Document:AXA/2025/FY/Earnings presentation: Difference between revisions
Appearance
Content deleted Content added
doc_archive: publish snjra2xp9r (original transcript) (.md link) |
doc_archive: publish snjra2xp9r (original transcript) |
||
| Line 11: | Line 11: | ||
| source_url = https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf |
| source_url = https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf |
||
| wide = yes |
| wide = yes |
||
| original_md = |
| original_md = <!-- ARCHIVE_MD_LINK_HERE --> |
||
| docling_file = |
| docling_file = <!-- ARCHIVE_DOCLING_LINK_HERE --> |
||
| article = AXA/2025/FY/Earnings presentation |
| article = AXA/2025/FY/Earnings presentation |
||
| doc_id = snjra2xp9r |
| doc_id = snjra2xp9r |
||
| Line 20: | Line 20: | ||
--- |
--- |
||
title: https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf |
title: https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf |
||
source_file: |
source_file: tmpmdo3mk_v.pdf |
||
source_url: https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf |
source_url: https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf |
||
doc_type: slides |
doc_type: slides |
||
pages: 49 |
pages: 49 |
||
tables: |
tables: 52 |
||
converter: anchor_injection/1 |
converter: anchor_injection/1 |
||
tier: slides |
tier: slides |
||
parsed_at: '2026-07- |
parsed_at: '2026-07-22T15:01:05Z' |
||
scanned_pages: [] |
scanned_pages: [] |
||
residue: |
residue: |
||
- '- February 26, 2026' |
- '- February 26, 2026' |
||
- Table of contents |
- Table of contents |
||
- Underlying Earnings |
|||
- '- 4. Sustainability p.44' |
- '- 4. Sustainability p.44' |
||
--- |
--- |
||
| Line 38: | Line 39: | ||
{{pdf page|1|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|1|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
=== Full Year 2025 Earnings Presentation === |
=== Full Year 2025 Earnings Presentation === |
||
* Full Year 2025 |
|||
* Earnings Presentation |
|||
{{pdf page|2|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|2|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
=== IMPORTANT LEGAL INFORMATION AND CAUTIONARY STATEMENTS CONCERNING FORWARD-LOOKING STATEMENTS AND THE USE OF NON-GAAP FINANCIAL MEASURES === |
=== IMPORTANT LEGAL INFORMATION AND CAUTIONARY STATEMENTS CONCERNING FORWARD-LOOKING STATEMENTS AND THE USE OF NON-GAAP FINANCIAL MEASURES === |
||
* Certain statements contained herein may be forward-looking statements including, but not limited to, statements that are predictions of or indicate future events, trends, plans, expectations or objectives, and other information that is not historical information. Forward-looking statements are generally identified by words and expressions such as |
* Certain statements contained herein may be forward-looking statements including, but not limited to, statements that are predictions of or indicate future events, trends, plans, expectations or objectives, and other information that is not historical information. Forward-looking statements are generally identified by words and expressions such as “expects”, “anticipates”, “may”, “plan,” “target” or any variations or similar terminology of these words and expressions, or conditional verbs such as, without limitations, “would” and “could”. In particular, the statements in this presentation regarding expected underlying earnings per share (“UEPS”) growth for 2026 are forward-looking statements to provide one-off guidance in the context of the last year of the Group’s current strategic plan. These statements in this presentation are based on Management’s current views and intentions and are subject to change. Undue reliance should not be placed on forward-looking statements because, by their nature, they are subject to known and unknown risks and uncertainties, many of which are outside AXA’s control, and can be affected by other factors that could cause AXA’s actual results to differ materially from those expressed in, or implied or projected by, such forward-looking statements. Each forward-looking statement speaks only at the date of this presentation. Please refer to Part 5 - “Risk Factors and Risk Management” of AXA’s Universal Registration Document for the year ended December 31, 2024 (the “2024 Universal Registration Document”) for a description of certain important factors, risks and uncertainties that may affect AXA’s business and/or results of operations. AXA specifically disclaims and undertakes no obligation to publicly update or revise any of these forward-looking statements, whether to reflect new information, future events or circumstances or otherwise, except as required by applicable laws and regulations. |
||
* In addition, this presentation refers to certain non-GAAP financial measures, or alternative performance measures ( |
* In addition, this presentation refers to certain non-GAAP financial measures, or alternative performance measures (“APMs”), used by Management in analyzing AXA’s operating trends, financial performance and financial position and providing investors with additional information that Management believes to be useful and relevant regarding AXA’s results. These non-GAAP financial measures generally have no standardized meaning and therefore may not be comparable to similarly labelled measures used by other companies. As a result, none of these non-GAAP financial measures should be considered in isolation from, or as a substitute for, the Group’s consolidated financial statements and related notes prepared in accordance with IFRS. “Underlying earnings”, UEPS (“underlying earnings per share”), “underlying return on equity”, “combined ratio” and “debt gearing” are APMs as defined in ESMA’s guidelines and the AMF’s related position statement issued in 2015. AXA provides a reconciliation of such APMs to the most closely related line item, subtotal, or total in the financial statements of the corresponding period (and/or their calculation methodology, as applicable) in its Activity Report as of December 31, 2025 (“AXA’s 2025 Activity Report”), on the pages indicated under the heading “USE OF NON-GAAP AND ALTERNATIVE PERFORMANCE MEASURES”. For further information on the above-mentioned and other non-GAAP financial measures used in this presentation, see the Glossary in AXA’s 2025 Activity Report. |
||
* |
* AXA’s Activity Report as of December 31, 2025 is available on the AXA Group website (www.axa.com). |
||
* |
* AXA’s consolidated financial statements for the year ended December 31, 2025 were examined by the Board of Directors on February 25, 2026, and are subject to completion of an audit procedure by AXA’s statutory auditors. |
||
{{pdf page|3|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|3|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
| Line 71: | Line 69: | ||
* 16% ROE FY25 |
* 16% ROE FY25 |
||
* 224% Solvency II ratio FY25 |
* 224% Solvency II ratio FY25 |
||
* Delivering value for shareholders +8% DPS{{fn ref|1|2=Based on the dividend proposed by |
* Delivering value for shareholders +8% DPS{{fn ref|1|2=Based on the dividend proposed by AXA’s Board of Directors on February 25, 2026 and subject to approval by the Shareholders’ Annual General Meeting to be held on April 30, 2026.}} growth and €1.25bn annual share buy back{{fn ref|2|2=Following AXA’s Board of Directors’ approval on February 25, 2026, and expected to commence as soon as reasonably practicable, subject to market conditions.}} |
||
* Confident to deliver underlying EPS growth at the upper end of 6%-8% target range for 2026 |
* Confident to deliver underlying EPS growth at the upper end of 6%-8% target range for 2026 |
||
<div class="ed-fn-notes" style="display:none"> |
<div class="ed-fn-notes" style="display:none"> |
||
{{fn note|1=1|2=Based on the dividend proposed by |
{{fn note|1=1|2=Based on the dividend proposed by AXA’s Board of Directors on February 25, 2026 and subject to approval by the Shareholders’ Annual General Meeting to be held on April 30, 2026.}} |
||
{{fn note|1=2|2=Following |
{{fn note|1=2|2=Following AXA’s Board of Directors’ approval on February 25, 2026, and expected to commence as soon as reasonably practicable, subject to market conditions.}} |
||
</div> |
</div> |
||
| Line 86: | Line 84: | ||
|+ Underlying earnings (In Euro billion) |
|+ Underlying earnings (In Euro billion) |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | Period |
||
! class="col-s" style="text-align:right" | |
! class="col-s" style="text-align:right" | Underlying earnings |
||
! class="col-s" style="text-align:right" | FY25 |
|||
! class="col-s" style="text-align:right" | Change |
! class="col-s" style="text-align:right" | Change |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | FY24 |
||
| style="text-align:right" | 8.1 |
| style="text-align:right" | 8.1 |
||
| style="text-align:right" | |
|||
|- |
|||
| style="text-align:left" | FY25 |
|||
| style="text-align:right" | 8.4 |
| style="text-align:right" | 8.4 |
||
| style="text-align:right" | +6% |
| style="text-align:right" | +6% |
||
|- |
|||
| style="text-align:left" | FY25 excluding AXA IM |
|||
| style="text-align:right" | |
|||
| style="text-align:right" | +9% |
|||
|} |
|} |
||
</div> |
</div> |
||
* +9% excluding AXA IM |
|||
* High organic growth: +6% top line growth, well balanced across lines (P&C: +5%, Life: +9%, Health: +5%) |
* High organic growth: +6% top line growth, well balanced across lines (P&C: +5%, Life: +9%, Health: +5%) |
||
* Record profitability: Further margin expansion in P&C and L&H; improvement in efficiency |
* Record profitability: Further margin expansion in P&C and L&H; improvement in efficiency |
||
| Line 118: | Line 121: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id="t2" class="wikitable fintable" |
{| id="t2" class="wikitable fintable" |
||
|+ FY25 gross written premium split excluding AXA IM and holdings |
|+ Pie chart represents FY25 gross written premium split excluding AXA IM and holdings. |
||
|- |
|- |
||
! style="text-align:left" | Business Segment |
! style="text-align:left" | Business Segment |
||
| Line 173: | Line 176: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id="t3" class="wikitable" |
{| id="t3" class="wikitable" |
||
|+ Strong delivery across our businesses |
|||
|+ Gross written premiums and Underlying earnings |
|||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
| Line 216: | Line 219: | ||
* 2025: Profitable growth with stable margins |
* 2025: Profitable growth with stable margins |
||
* Beyond 2025: Capitalizing on attractive growth opportunities and continued cycle management |
* Beyond 2025: Capitalizing on attractive growth opportunities and continued cycle management |
||
==== Key Drivers ==== |
|||
* Continued progress on efficiency |
* Continued progress on efficiency |
||
* Higher investment income |
* Higher investment income |
||
| Line 228: | Line 234: | ||
=== L&H – Good momentum, well positioned to capture growth opportunities === |
=== L&H – Good momentum, well positioned to capture growth opportunities === |
||
* |
* €57bn GWP |
||
* GWP mix: |
|||
* Short-term |
|||
* |
** Short-term |
||
** Long-term |
|||
* Underlying earnings: +7%{{fn ref|1|2=1. Change FY25 vs. FY24 at constant FX.}} to €3.5bn |
|||
* Underlying earnings +7%{{fn ref|1|2=1. Change FY25 vs. FY24 at constant FX.}} to €3.5bn |
|||
==== Strategic Priorities ==== |
|||
==== Strategic Roadmap ==== |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id="t4" class="wikitable" |
{| id="t4" class="wikitable" |
||
|+ Strategic Priorities by Business Line |
|||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
| Line 255: | Line 261: | ||
* Focus on cost reduction |
* Focus on cost reduction |
||
* Increasing penetration of Protection riders in Savings offerings |
* Increasing penetration of Protection riders in Savings offerings |
||
* Leveraging AI to reduce claims leakage & improve |
* Leveraging AI to reduce claims leakage & improve customer outcomes in Health |
||
<div class="ed-fn-notes" style="display:none"> |
<div class="ed-fn-notes" style="display:none"> |
||
| Line 269: | Line 275: | ||
{{pdf page|14|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|14|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
=== P&C – Continued disciplined growth === |
=== P&C – Continued disciplined growth === |
||
In Euro billion |
|||
* In Euro billion |
|||
==== GWP & Other Revenues ==== |
==== GWP & Other Revenues ==== |
||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id="t5" class="wikitable fintable" |
{| id="t5" class="wikitable fintable" |
||
| Line 282: | Line 290: | ||
! class="col-s" style="text-align:right" | o/w pricing{{fn ref|1|2=Price effect.}} |
! class="col-s" style="text-align:right" | o/w pricing{{fn ref|1|2=Price effect.}} |
||
! class="col-s" style="text-align:right" | o/w volume{{fn ref|2|2=Includes exposure adjustments and mix & other effects.}} |
! class="col-s" style="text-align:right" | o/w volume{{fn ref|2|2=Includes exposure adjustments and mix & other effects.}} |
||
|- |
|||
| style="text-align:left" | Total |
|||
| style="text-align:right" | 56.5 |
|||
| style="text-align:right" | 58.0 |
|||
| style="text-align:right" | +5% |
|||
| style="text-align:right" | |
|||
| style="text-align:right" | |
|||
|- |
|- |
||
| style="text-align:left" | Commercial lines |
| style="text-align:left" | Commercial lines |
||
| Line 310: | Line 311: | ||
| style="text-align:right" | +5% |
| style="text-align:right" | +5% |
||
| style="text-align:right" | +2% |
| style="text-align:right" | +2% |
||
|- |
|||
| style="text-align:left" | Total |
|||
| style="text-align:right" | 56.5 |
|||
| style="text-align:right" | 58.0 |
|||
| style="text-align:right" | +5% |
|||
| style="text-align:right" | |
|||
| style="text-align:right" | |
|||
|} |
|} |
||
</div> |
</div> |
||
| Line 318: | Line 326: | ||
* Favorable pricing trends and strong growth in net new contracts (+1.7m in FY25) |
* Favorable pricing trends and strong growth in net new contracts (+1.7m in FY25) |
||
Change at constant scope and FX. |
|||
<div class="ed-fn-notes" style="display:none"> |
<div class="ed-fn-notes" style="display:none"> |
||
{{fn note|1=1|2=Price effect.}} |
{{fn note|1=1|2=Price effect.}} |
||
| Line 336: | Line 343: | ||
! class="col-s" style="text-align:right" | FY24 |
! class="col-s" style="text-align:right" | FY24 |
||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
|- |
|||
| style="text-align:left" | Combined ratio |
|||
| style="text-align:right" | 91.0% |
|||
| style="text-align:right" | 90.6% |
|||
|- |
|- |
||
| style="text-align:left" | Undiscounted CY loss ratio (ex Nat Cat) |
| style="text-align:left" | Undiscounted CY loss ratio (ex Nat Cat) |
||
| Line 360: | Line 363: | ||
| style="text-align:right" | -3.6% |
| style="text-align:right" | -3.6% |
||
| style="text-align:right" | -3.5% |
| style="text-align:right" | -3.5% |
||
|- |
|||
| style="text-align:left" | Total Combined ratio |
|||
| style="text-align:right" | 91.0% |
|||
| style="text-align:right" | 90.6% |
|||
|} |
|} |
||
</div> |
</div> |
||
| Line 370: | Line 377: | ||
* Lower reliance on prior year reserve development |
* Lower reliance on prior year reserve development |
||
* Taking advantage of a good year to enhance reserve prudence |
* Taking advantage of a good year to enhance reserve prudence |
||
<!-- furniture --> |
|||
{{pdf page|16|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|16|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
| Line 375: | Line 384: | ||
* In Euro million |
* In Euro million |
||
==== Underlying Earnings ==== |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id="t7" class="wikitable fintable" |
{| id="t7" class="wikitable fintable" |
||
|+ Underlying Earnings (in Euro million) |
|+ Underlying Earnings (in Euro million) |
||
|- |
|||
! style="text-align:left" | Driver |
|||
! class="col-s" style="text-align:right" | Value |
|||
|- |
|- |
||
| style="text-align:left" | FY24 |
| style="text-align:left" | FY24 |
||
| style="text-align:right" | 5,510 |
| style="text-align:right" | 5,510 |
||
|- |
|- |
||
| style="text-align:left" | Volume growth |
| style="text-align:left" | Volume growth {{fn ref|1|2=Underwriting result includes expenses.}} |
||
| style="text-align:right" | +292 |
| style="text-align:right" | +292 |
||
|- |
|- |
||
| style="text-align:left" | Margin improvement |
| style="text-align:left" | Margin improvement {{fn ref|1|2=Underwriting result includes expenses.}} |
||
| style="text-align:right" | +189 |
| style="text-align:right" | +189 |
||
|- |
|- |
||
| style="text-align:left" | Investment income |
| style="text-align:left" | Investment income (Financial result) |
||
| style="text-align:right" | +435 |
| style="text-align:right" | +435 |
||
|- |
|- |
||
| style="text-align:left" | Insurance finance expenses |
| style="text-align:left" | Insurance finance expenses (Financial result) |
||
| style="text-align:right" | -235 |
| style="text-align:right" | -235 |
||
|- |
|- |
||
| Line 406: | Line 416: | ||
| style="text-align:right" | 5,872 |
| style="text-align:right" | 5,872 |
||
|- |
|- |
||
| style="text-align:left" | Change at constant FX |
| style="text-align:left" | Total Change at constant FX |
||
| style="text-align:right" | +9% |
| style="text-align:right" | +9% |
||
|} |
|} |
||
</div> |
</div> |
||
* Better underwriting result |
* Better underwriting result from strong volume growth and improved all-year combined ratio while enhancing reserve prudence |
||
* Increase in investment income reflecting higher volumes and better reinvestment yields on fixed income assets |
* Increase in investment income reflecting higher volumes and better reinvestment yields on fixed income assets |
||
* Higher unwind of discount of claims reserves, in line with guidance |
* Higher unwind of discount of claims reserves, in line with guidance |
||
| Line 421: | Line 431: | ||
* Change at constant FX. |
* Change at constant FX. |
||
* Full Year 2025 Earnings |
|||
{{pdf page|17|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|17|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
| Line 430: | Line 439: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id="t8" class="wikitable fintable" |
{| id="t8" class="wikitable fintable" |
||
|+ Life GWP & Other Revenues |
|+ Life GWP & Other Revenues (in Euro billion) |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
! class="col-s" style="text-align:right" | FY24 |
! class="col-s" style="text-align:right" | FY24 |
||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
| Line 457: | Line 466: | ||
| style="text-align:right" | -7% |
| style="text-align:right" | -7% |
||
|- |
|- |
||
| style="text-align:left" | Total |
| style="text-align:left" | Total |
||
| style="text-align:right" | 34.5 |
| style="text-align:right" | 34.5 |
||
| style="text-align:right" | 37.5 |
| style="text-align:right" | 37.5 |
||
| Line 466: | Line 475: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id="t9" class="wikitable fintable" |
{| id="t9" class="wikitable fintable" |
||
|+ Health GWP & Other Revenues |
|+ Health GWP & Other Revenues (in Euro billion) |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
! class="col-s" style="text-align:right" | FY24 |
! class="col-s" style="text-align:right" | FY24 |
||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
| Line 483: | Line 492: | ||
| style="text-align:right" | +4% |
| style="text-align:right" | +4% |
||
|- |
|- |
||
| style="text-align:left" | Total |
| style="text-align:left" | Total |
||
| style="text-align:right" | 17.5 |
| style="text-align:right" | 17.5 |
||
| style="text-align:right" | 19.0 |
| style="text-align:right" | 19.0 |
||
| Line 494: | Line 503: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id="t10" class="wikitable fintable" |
{| id="t10" class="wikitable fintable" |
||
|+ Net flows: €+5.4bn vs. €+1.5bn in FY24 |
|+ Net flows: €+5.4bn vs. €+1.5bn in FY24 (in Euro billion) |
||
|- |
|||
! style="text-align:left" | (in Euro billion) |
|||
! class="col-s" style="text-align:right" | FY25 |
|||
|- |
|- |
||
| style="text-align:left" | Protection |
| style="text-align:left" | Protection |
||
| Line 526: | Line 532: | ||
* In Euro billion |
* In Euro billion |
||
* PVEP was impacted by higher interest rates on discounting despite strong growth in Life volumes |
|||
* NB CSM was driven by robust Savings & Protection sales, with reported growth impacted by higher interest rates for discounting of future profits |
|||
* NBV was broadly stable as strong growth in NB CSM balanced lower contribution from short-term multinational business in France |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id="t11" class="wikitable fintable" |
{| id="t11" class="wikitable fintable" |
||
|+ PVEP |
|+ PVEP (in Euro billion) |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
! class="col-s" style="text-align:right" | FY24 |
! class="col-s" style="text-align:right" | FY24 |
||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
| Line 565: | Line 574: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id="t12" class="wikitable fintable" |
{| id="t12" class="wikitable fintable" |
||
|+ NB CSM (pre-tax) |
|+ NB CSM (pre-tax) (in Euro billion) |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
! class="col-s" style="text-align:right" | FY24 |
! class="col-s" style="text-align:right" | FY24 |
||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
| Line 581: | Line 590: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id="t13" class="wikitable fintable" |
{| id="t13" class="wikitable fintable" |
||
|+ NBV (post-tax) |
|+ NBV (post-tax) (in Euro billion) |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
! class="col-s" style="text-align:right" | FY24 |
! class="col-s" style="text-align:right" | FY24 |
||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
| Line 599: | Line 608: | ||
|} |
|} |
||
</div> |
</div> |
||
* PVEP was impacted by higher interest rates on discounting despite strong growth in Life volumes |
|||
* NB CSM was driven by robust Savings & Protection sales, with reported growth impacted by higher interest rates for discounting of future profits |
|||
* NBV was broadly stable as strong growth in NB CSM balanced lower contribution from short-term multinational business in France |
|||
* Change at constant scope and FX. |
* Change at constant scope and FX. |
||
| Line 615: | Line 620: | ||
* Operating variance driven by better margins and net flows that were more than offset by a reduction in the duration of Group Life business in Switzerland |
* Operating variance driven by better margins and net flows that were more than offset by a reduction in the duration of Group Life business in Switzerland |
||
* FX impact mainly from JPY and HKD depreciation |
* FX impact mainly from JPY and HKD depreciation |
||
==== Contractual Service Margin rollforward ==== |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id="t14" class="wikitable fintable" |
{| id="t14" class="wikitable fintable" |
||
|+ Contractual Service Margin rollforward |
|+ Contractual Service Margin rollforward (in Euro billion) |
||
|- |
|- |
||
! style="text-align:left" | Item |
|||
! class="col-s" style="text-align:right" | Value |
|||
|- |
|- |
||
| style="text-align:left" | FY24 |
| style="text-align:left" | FY24 |
||
| style="text-align:right" | 33.6 |
| style="text-align:right" | 33.6 |
||
|- |
|||
| style="text-align:left" | o/w Life |
|||
| style="text-align:right" | 25.8 |
|||
|- |
|||
| style="text-align:left" | o/w Health |
|||
| style="text-align:right" | 7.7 |
|||
|- |
|- |
||
| style="text-align:left" | New business CSM |
| style="text-align:left" | New business CSM |
||
| Line 652: | Line 653: | ||
| style="text-align:left" | FY25 |
| style="text-align:left" | FY25 |
||
| style="text-align:right" | 33.0 |
| style="text-align:right" | 33.0 |
||
|} |
|||
</div> |
|||
<div style="overflow-x:auto"> |
|||
{| id="t15" class="wikitable fintable" |
|||
|+ CSM breakdown by segment (in Euro billion) |
|||
|- |
|||
! style="text-align:left" | Segment |
|||
! class="col-s" style="text-align:right" | FY24 |
|||
! class="col-s" style="text-align:right" | FY25 |
|||
|- |
|- |
||
| style="text-align:left" | o/w Life |
| style="text-align:left" | o/w Life |
||
| style="text-align:right" | 25.8 |
|||
| style="text-align:right" | 25.4 |
| style="text-align:right" | 25.4 |
||
|- |
|- |
||
| style="text-align:left" | o/w Health |
| style="text-align:left" | o/w Health |
||
| style="text-align:right" | 7.7 |
|||
| style="text-align:right" | 7.6 |
| style="text-align:right" | 7.6 |
||
|} |
|} |
||
| Line 665: | Line 678: | ||
{{pdf page|20|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|20|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
=== Life & Health – Strong momentum in both short-term and long-term business === |
=== Life & Health – Strong momentum in both short-term and long-term business === |
||
In Euro million |
|||
==== Underlying Earnings ==== |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t16" class="wikitable fintable" |
||
|+ Underlying Earnings |
|+ Underlying Earnings (in Euro million) |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | Component |
||
! class="col-s" style="text-align:right" | FY24 |
! class="col-s" style="text-align:right" | FY24 |
||
! class="col-s" style="text-align:right" | |
! class="col-s" style="text-align:right" | Bridge |
||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
|- |
|- |
||
| Line 692: | Line 703: | ||
| style="text-align:right" | 946 |
| style="text-align:right" | 946 |
||
|- |
|- |
||
| style="text-align:left" | Tax & others |
| style="text-align:left" | Tax & others / Tax, FX and others |
||
| style="text-align:right" | -748 |
| style="text-align:right" | -748 |
||
| style="text-align:right" | -27 |
| style="text-align:right" | -27 |
||
| style="text-align:right" | -728 |
| style="text-align:right" | -728 |
||
|- |
|- |
||
! style="text-align:left" | Total Underlying Earnings |
|||
! class="col-s" style="text-align:right" | 3,323 |
|||
! class="col-s" style="text-align:right" | +7%{{fn ref|*|2=Change at constant FX.}} |
|||
! class="col-s" style="text-align:right" | 3,501 |
|||
|} |
|} |
||
</div> |
</div> |
||
<div style="overflow-x:auto"> |
|||
in billions |
|||
{| id="t17" class="wikitable fintable" |
|||
* o/w Life: 2.6 → 2.7, +4% vs. FY24 |
|||
|+ Additional Metrics (in billions) |
|||
* o/w Health: 0.7 → 0.8, +17% vs. FY24 |
|||
|- |
|||
! style="text-align:left" | Metric |
|||
! class="col-s" style="text-align:right" | FY24 |
|||
! class="col-s" style="text-align:right" | FY25 |
|||
! class="col-s" style="text-align:right" | Change vs. FY24{{fn ref|*|2=Change at constant FX.}} |
|||
|- |
|||
| style="text-align:left" | o/w Life |
|||
| style="text-align:right" | 2.6 |
|||
| style="text-align:right" | 2.7 |
|||
| style="text-align:right" | +4% |
|||
|- |
|||
| style="text-align:left" | o/w Health |
|||
| style="text-align:right" | 0.7 |
|||
| style="text-align:right" | 0.8 |
|||
| style="text-align:right" | +17% |
|||
|} |
|||
</div> |
|||
* Strong short-term technical margin reflecting underwriting and claims initiatives that more than offset the impact of legislative change on the recoverability of value added tax in Mexico (€-0.1bn) |
* Strong short-term technical margin reflecting underwriting and claims initiatives that more than offset the impact of legislative change on the recoverability of value added tax in Mexico (€-0.1bn) |
||
* Higher long-term results from increase in CSM release (+8%) reflecting growth in reserve base, including from favorable equity market performance, and better margins |
* Higher long-term results from increase in CSM release (+8%) reflecting growth in reserve base, including from favorable equity market performance, and better margins |
||
<div class="ed-fn-notes" style="display:none"> |
|||
Change at constant FX. |
|||
{{fn note|1=*|2=Change at constant FX.}} |
|||
</div> |
|||
{{pdf page|21|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|21|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
| Line 717: | Line 747: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t18" class="wikitable fintable" |
||
|+ In Euro billion |
|+ In Euro billion |
||
|- |
|- |
||
| Line 772: | Line 802: | ||
</div> |
</div> |
||
==== Underlying earnings per share ==== |
|||
* Strong performance from insurance businesses |
|||
* Stable holding cost, expected to remain at current level in 2026 |
|||
* Net Income |
|||
* Higher net income mainly reflecting higher underlying earnings and the gain from the sale of AXA IM |
|||
* Lower financial flows reflecting unfavorable forex impact |
|||
==== Underlying earnings per share ==== |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t19" class="wikitable fintable" |
||
|+ In Euro |
|+ In Euro |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
! class="col-s" style="text-align:right" | FY24 |
|||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
! class="col-s" style="text-align:right" | Change |
! class="col-s" style="text-align:right" | Change |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | Underlying earnings per share |
||
| style="text-align:right" | 3.59 |
|||
| style="text-align:right" | 3.86 |
| style="text-align:right" | 3.86 |
||
| style="text-align:right" | +8% |
| style="text-align:right" | +8% |
||
| Line 795: | Line 821: | ||
* +6% from earnings growth |
* +6% from earnings growth |
||
* including -1% from temporary earnings dilution from AXA IM sale due to the timing of anti-dilutive share buyback |
|||
* +3% from capital management |
* +3% from capital management |
||
* -2% from forex |
* -2% from forex |
||
* including -1% from temporary earnings dilution from AXA IM sale due to the timing of anti-dilutive share buyback |
|||
* Underlying earnings |
|||
<div class="ed-fn-notes" style="display:none"> |
|||
* Strong performance from insurance businesses |
|||
{{fn note|1=1|2=Change at constant FX for underlying earnings and net income. Change on reported basis for underlying earnings per share.}} |
|||
* Stable holding cost, expected to remain at current level in 2026 |
|||
</div> |
|||
* Net Income |
|||
* Higher net income mainly reflecting higher underlying earnings and the gain from the sale of AXA IM |
|||
* Lower financial flows reflecting unfavorable forex impact |
|||
* Change at constant FX for underlying earnings and net income. Change on reported basis for underlying earnings per share. |
|||
{{pdf page|22|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|22|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
=== |
=== Shareholders’ Equity === |
||
* In Euro billion |
* In Euro billion |
||
==== Shareholders' equity{{fn ref|1|2=Shareholders' equity Group share.}} ==== |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t20" class="wikitable fintable" |
||
|+ |
|+ Shareholders’ equity{{fn ref|1|2=Shareholders’ equity Group share.}} |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
| Line 817: | Line 847: | ||
! class="col-s" style="text-align:right" | HY25 |
! class="col-s" style="text-align:right" | HY25 |
||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
|- |
|||
| style="text-align:left" | Total Shareholders' equity |
|||
| style="text-align:right" | 49.9 |
|||
| style="text-align:right" | 45.5 |
|||
| style="text-align:right" | 47.2 |
|||
|- |
|- |
||
| style="text-align:left" | SHE (excl. OCI) |
| style="text-align:left" | SHE (excl. OCI) |
||
| Line 828: | Line 863: | ||
| style="text-align:right" | -6.8 |
| style="text-align:right" | -6.8 |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | SHE (excl. OCI & undated subordinated debt) |
||
| style="text-align:right" | |
| style="text-align:right" | 53.2 |
||
| style="text-align:right" | |
| style="text-align:right" | 47.0 |
||
| style="text-align:right" | |
| style="text-align:right" | 49.4 |
||
|- |
|||
| style="text-align:left" | Debt gearing |
|||
| style="text-align:right" | 20.6% |
|||
| style="text-align:right" | 23.4% |
|||
| style="text-align:right" | 22.3% |
|||
|- |
|||
| style="text-align:left" | Underlying ROE |
|||
| style="text-align:right" | 15.2% |
|||
| style="text-align:right" | 17.5% |
|||
| style="text-align:right" | 16.0% |
|||
|} |
|} |
||
</div> |
</div> |
||
* SHE (excl. OCI & undated subordinated debt): 53.2 / 47.0 / 49.4 |
|||
* Debt gearing: 20.6% / 23.4% / 22.3% |
|||
* Underlying ROE: 15.2% / 17.5% / 16.0% |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t21" class="wikitable fintable" |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
| Line 889: | Line 930: | ||
<div class="ed-fn-notes" style="display:none"> |
<div class="ed-fn-notes" style="display:none"> |
||
{{fn note|1=1|2= |
{{fn note|1=1|2=Shareholders’ equity Group share.}} |
||
</div> |
</div> |
||
{{pdf page|23|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|23|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
=== Higher organic cash remittance and robust cash position at Holding === |
=== Higher organic cash remittance and robust cash position at Holding === |
||
In Euro billion |
|||
* In Euro billion |
|||
==== Net Cash Remittance ==== |
==== Net Cash Remittance ==== |
||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t22" class="wikitable fintable" |
||
|+ Net Cash Remittance (in Euro billion) |
|||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
| Line 913: | Line 956: | ||
| style="text-align:right" | 7.5 |
| style="text-align:right" | 7.5 |
||
|- |
|- |
||
| style="text-align:left" | Total |
| style="text-align:left" | Total Net Cash Remittance |
||
| style="text-align:right" | 7.7 |
| style="text-align:right" | 7.7 |
||
| style="text-align:right" | 7.5 |
| style="text-align:right" | 7.5 |
||
| Line 922: | Line 965: | ||
|} |
|} |
||
</div> |
</div> |
||
==== Cash Position Bridge ==== |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t23" class="wikitable fintable" |
||
|+ Cash position bridge (in Euro billion) |
|||
|- |
|||
! style="text-align:left" | |
|||
! class="col-s" style="text-align:right" | In Euro billion |
|||
|- |
|- |
||
| style="text-align:left" | FY24 Cash position |
| style="text-align:left" | FY24 Cash position |
||
| Line 955: | Line 994: | ||
| style="text-align:right" | +3.1 |
| style="text-align:right" | +3.1 |
||
|- |
|- |
||
! style="text-align:left" | FY25 Cash position |
|||
! class="col-s" style="text-align:right" | 5.6 |
|||
|} |
|} |
||
</div> |
</div> |
||
| Line 962: | Line 1,001: | ||
<div class="ed-fn-notes" style="display:none"> |
<div class="ed-fn-notes" style="display:none"> |
||
{{fn note|1=1|2=Based on ordinary cash remittance of Euro 7.1 billion in FY24 and Euro 7.5 billion in FY25.}} |
{{fn note|1=1|2=Based on ordinary cash remittance of Euro 7.1 billion in FY24 and Euro 7.5 billion in FY25.}} |
||
{{fn note|1=2|2=€0.6bn proceeds related to L&S reinsurance in-force treaties at AXA France and AXA Life Europe.}} |
{{fn note|1=2|2=€0.6bn proceeds related to L&S reinsurance in-force treaties at AXA France and AXA Life Europe.}} |
||
</div> |
</div> |
||
| Line 971: | Line 1,010: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t24" class="wikitable fintable" |
||
|+ Eligible Own Funds (EOF) waterfall |
|+ Eligible Own Funds (EOF), Solvency Capital Requirement (SCR), and Solvency II ratio waterfall from FY24 to FY25 |
||
|- |
|- |
||
! style="text-align:left" | |
|||
! class="col-s" style="text-align:right" | FY24 |
|||
! class="col-s" style="text-align:right" | Regulatory & model changes |
|||
! class="col-s" style="text-align:right" | Normalized capital generation |
|||
! class="col-s" style="text-align:right" | Operating variance |
|||
! class="col-s" style="text-align:right" | Economic variance & FX |
|||
! class="col-s" style="text-align:right" | Dividend & annual share buyback |
|||
! class="col-s" style="text-align:right" | Management actions, debt & other |
|||
! class="col-s" style="text-align:right" | FY25 |
|||
|- |
|||
| style="text-align:left" | Eligible Own Funds (EOF) |
|||
| style="text-align:right" | 55.9 |
| style="text-align:right" | 55.9 |
||
|- |
|||
| style="text-align:left" | Regulatory & model changes |
|||
| style="text-align:right" | +0.2 |
| style="text-align:right" | +0.2 |
||
|- |
|||
| style="text-align:left" | Normalized capital generation |
|||
| style="text-align:right" | +8.8 |
| style="text-align:right" | +8.8 |
||
|- |
|||
| style="text-align:left" | Operating variance |
|||
| style="text-align:right" | -0.4 |
| style="text-align:right" | -0.4 |
||
|- |
|||
| style="text-align:left" | Economic variance & FX |
|||
| style="text-align:right" | -2.1 |
| style="text-align:right" | -2.1 |
||
|- |
|||
| style="text-align:left" | Dividend & annual share buyback |
|||
| style="text-align:right" | -6.0 |
| style="text-align:right" | -6.0 |
||
|- |
|||
| style="text-align:left" | Management actions, debt & other |
|||
| style="text-align:right" | -0.1 |
| style="text-align:right" | -0.1 |
||
|- |
|||
| style="text-align:left" | FY25 |
|||
| style="text-align:right" | 56.4 |
| style="text-align:right" | 56.4 |
||
|} |
|||
</div> |
|||
* Foreseeable dividends: €-4.8bn |
|||
* Provision for annual share buyback for 2026: €-1.25bn |
|||
<div style="overflow-x:auto"> |
|||
{| id="t23" class="wikitable fintable" |
|||
|+ Solvency II ratio bridge |
|||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | Solvency II ratio |
||
| style="text-align:right" | 216% |
| style="text-align:right" | 216% |
||
|- |
|||
| style="text-align:left" | Regulatory & model changes |
|||
| style="text-align:right" | +0pt |
| style="text-align:right" | +0pt |
||
|- |
|||
| style="text-align:left" | Normalized capital generation |
|||
| style="text-align:right" | +28pts |
| style="text-align:right" | +28pts |
||
|- |
|||
| style="text-align:left" | Operating variance |
|||
| style="text-align:right" | -1pt |
| style="text-align:right" | -1pt |
||
|- |
|||
| style="text-align:left" | Economic variance & FX |
|||
| style="text-align:right" | +4pts |
| style="text-align:right" | +4pts |
||
|- |
|||
| style="text-align:left" | Dividend & annual share buyback |
|||
| style="text-align:right" | -24pts |
| style="text-align:right" | -24pts |
||
|- |
|||
| style="text-align:left" | Management actions, debt & other |
|||
| style="text-align:right" | +2pts |
| style="text-align:right" | +2pts |
||
|- |
|||
| style="text-align:left" | FY25 |
|||
| style="text-align:right" | 224% |
| style="text-align:right" | 224% |
||
|} |
|||
</div> |
|||
<div style="overflow-x:auto"> |
|||
{| id="t24" class="wikitable fintable" |
|||
|+ Solvency Capital Requirement (SCR) waterfall |
|||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | Solvency Capital Requirement (SCR) |
||
| style="text-align:right" | 25.9 |
| style="text-align:right" | 25.9 |
||
|- |
|||
| style="text-align:left" | Regulatory & model changes |
|||
| style="text-align:right" | 0.0 |
| style="text-align:right" | 0.0 |
||
|- |
|||
| style="text-align:left" | Normalized capital generation |
|||
| style="text-align:right" | +0.6 |
| style="text-align:right" | +0.6 |
||
|- |
|||
| style="text-align:left" | Operating variance |
|||
| style="text-align:right" | 0.0 |
| style="text-align:right" | 0.0 |
||
|- |
|||
| style="text-align:left" | Economic variance & FX |
|||
| style="text-align:right" | -1.2 |
| style="text-align:right" | -1.2 |
||
|- |
|||
| style="text-align:left" | Dividend & annual share buyback |
|||
| style="text-align:right" | 0.0 |
| style="text-align:right" | 0.0 |
||
|- |
|||
| style="text-align:left" | Management actions, debt & other |
|||
| style="text-align:right" | -0.2 |
| style="text-align:right" | -0.2 |
||
|- |
|||
| style="text-align:left" | FY25 |
|||
| style="text-align:right" | 25.2 |
| style="text-align:right" | 25.2 |
||
|} |
|} |
||
</div> |
</div> |
||
* Foreseeable dividends: €-4.8bn |
|||
* Provision for annual share buyback for 2026: €-1.25bn |
|||
==== Key sensitivities ==== |
==== Key sensitivities ==== |
||
| Line 1,087: | Line 1,082: | ||
|- |
|- |
||
| style="text-align:left" | Listed Equity (excl. PE & Infra) +25% |
| style="text-align:left" | Listed Equity (excl. PE & Infra) +25% |
||
| style="text-align:right" | |
| style="text-align:right" | -1 pt |
||
|- |
|- |
||
| style="text-align:left" | Listed Equity (excl. PE & Infra) -25% |
| style="text-align:left" | Listed Equity (excl. PE & Infra) -25% |
||
| style="text-align:right" | |
| style="text-align:right" | +2 pts |
||
|- |
|- |
||
| style="text-align:left" | PE & Infra +25% |
| style="text-align:left" | PE & Infra +25% |
||
| style="text-align:right" | + |
| style="text-align:right" | +14 pts |
||
|- |
|- |
||
| style="text-align:left" | PE & Infra -25% |
| style="text-align:left" | PE & Infra -25% |
||
| style="text-align:right" | - |
| style="text-align:right" | -19 pts |
||
|- |
|- |
||
| style="text-align:left" | Inflation swap curve +50bps |
| style="text-align:left" | Inflation swap curve +50bps |
||
| Line 1,113: | Line 1,108: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id="t26" class="wikitable fintable" |
{| id="t26" class="wikitable fintable" |
||
|+ Solvency II Ratio Impacts |
|||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | Metric / Event |
||
! class="col- |
! class="col-m" style="text-align:right" | Impact / Ratio |
||
! class="col-s" style="text-align:right" | Ratio |
|||
|- |
|- |
||
| style="text-align:left" | Ratio as of 31/12/2025 |
| style="text-align:left" | Ratio as of 31/12/2025 |
||
| style="text-align:right" | |
|||
| style="text-align:right" | 224% |
| style="text-align:right" | 224% |
||
|- |
|- |
||
| style="text-align:left" | Impact of the end of grandfathering period on January 1, 2026 |
| style="text-align:left" | Impact of the end of grandfathering period on January 1, 2026 |
||
| style="text-align:right" | -10pts |
| style="text-align:right" | -10pts to 215% |
||
| style="text-align:right" | 215% |
|||
|- |
|- |
||
| style="text-align:left" | Impact of Solvency II revision to come into effect in 1Q27 |
| style="text-align:left" | Impact of Solvency II revision to come into effect in 1Q27 |
||
| style="text-align:right" | +17pts{{fn ref|1|2=Estimated based on the Solvency Capital Requirement (SCR) and the amount of capital (EOF) under Solvency II as of January 1, 2026, as if the Solvency II revision had come into force on the same date.}} |
| style="text-align:right" | +17pts{{fn ref|1|2=Estimated based on the Solvency Capital Requirement (SCR) and the amount of capital (EOF) under Solvency II as of January 1, 2026, as if the Solvency II revision had come into force on the same date.}} |
||
| style="text-align:right" | |
|||
|} |
|} |
||
</div> |
</div> |
||
| Line 1,154: | Line 1,146: | ||
{{pdf page|28|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|28|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
== Q&A |
== Q&A == |
||
* Full Year 2025 Earnings |
|||
{{pdf page|29|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|29|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
| Line 1,161: | Line 1,154: | ||
==== Meet our management ==== |
==== Meet our management ==== |
||
* March: Roadshows |
* March: Roadshows — Europe and US |
||
* May 5: 1Q25 Activity Indicators |
* May 5: 1Q25 Activity Indicators — Paris |
||
* June 2: BNP Paribas Exane CEO Conference |
* June 2: BNP Paribas Exane CEO Conference — Paris |
||
* June 2-4: Goldman Sachs European Financials Conference |
* June 2-4: Goldman Sachs European Financials Conference — Zurich |
||
* July 31: HY26 Earnings Release |
* July 31: HY26 Earnings Release — Paris |
||
* September 21: AXA Investor Day |
* September 21: AXA Investor Day — London |
||
==== Contact us ==== |
==== Contact us ==== |
||
| Line 1,174: | Line 1,167: | ||
* investor.relations@axa.com |
* investor.relations@axa.com |
||
==== Follow us ==== |
==== Follow us www.axa.com ==== |
||
* YouTube |
|||
* www.axa.com |
|||
* Facebook |
|||
* Instagram |
|||
* Twitter |
|||
* LinkedIn |
|||
* AXA logo icon |
|||
{{pdf page|30|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|30|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
| Line 1,191: | Line 1,189: | ||
* In Euro billion |
* In Euro billion |
||
==== Gross financial debt |
==== Gross financial debt{{fn ref|1,2}} ==== |
||
* Debt gearing: 20.6% (FY24), 22.3% (FY25) |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id="t27" class="wikitable fintable" |
{| id="t27" class="wikitable fintable" |
||
|+ Gross financial debt |
|+ Gross financial debt{{fn ref|1,2}} |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
| Line 1,223: | Line 1,221: | ||
|} |
|} |
||
</div> |
</div> |
||
* o/w €0.4bn redeemed in Jan 2026 (Tier 2, Jan 1st 2026) |
|||
* Debt gearing 20.6% FY24, 22.3% FY25 |
|||
* o/w €0.4bn redeemed in Jan 2026 |
|||
* End of the grandfathering period |
* End of the grandfathering period |
||
==== Contractual maturity breakdown ==== |
==== Contractual maturity breakdown ==== |
||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id="t28" class="wikitable fintable" |
{| id="t28" class="wikitable fintable" |
||
|+ Contractual maturity breakdown |
|+ Contractual maturity breakdown |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
| Line 1,253: | Line 1,248: | ||
| style="text-align:right" | 0.9 |
| style="text-align:right" | 0.9 |
||
| style="text-align:right" | 1.5 |
| style="text-align:right" | 1.5 |
||
| style="text-align:right" | |
| style="text-align:right" | - |
||
| style="text-align:right" | 0.7 |
| style="text-align:right" | 0.7 |
||
|- |
|- |
||
| Line 1,279: | Line 1,274: | ||
|} |
|} |
||
</div> |
</div> |
||
* o/w Grandfathered debt |
|||
==== o/w Grandfathered debt ==== |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id="t29" class="wikitable fintable" |
{| id="t29" class="wikitable fintable" |
||
|+ o/w Grandfathered debt |
|+ o/w Grandfathered debt |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
| Line 1,321: | Line 1,314: | ||
</div> |
</div> |
||
==== Economic maturity breakdown{{fn ref|3|2=Economic maturity is taking into account the first date of step up calls on institutionally placed subordinated debt. For Solvency 2 RT1 debt, that has no step-up, the undated nature of the instrument is retained for the purpose of this diagram. This should not be construed, nor relied upon, as an indication that the instrument will not be called for redemption when callable. Such decision will depend on several factors, including our capital and liquidity position and the refinancing economics at the prevailing time.}} ==== |
|||
==== Economic maturity breakdown³ ==== |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id="t30" class="wikitable fintable" |
{| id="t30" class="wikitable fintable" |
||
|+ Economic maturity breakdown{{fn ref|3|2=Economic maturity is taking into account the first date of step up calls on institutionally placed subordinated debt. For Solvency 2 RT1 debt, that has no step-up, the undated nature of the instrument is retained for the purpose of this diagram. This should not be construed, nor relied upon, as an indication that the instrument will not be called for redemption when callable. Such decision will depend on several factors, including our capital and liquidity position and the refinancing economics at the prevailing time.}} |
|||
|+ Economic maturity breakdown³ (In Euro billion) |
|||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
| Line 1,342: | Line 1,334: | ||
| style="text-align:right" | - |
| style="text-align:right" | - |
||
| style="text-align:right" | - |
| style="text-align:right" | - |
||
| style="text-align:right" | |
| style="text-align:right" | 0.5 |
||
| style="text-align:right" | - |
| style="text-align:right" | - |
||
| style="text-align:right" | 0.9 |
| style="text-align:right" | 0.9 |
||
| style="text-align:right" | 1.5 |
| style="text-align:right" | 1.5 |
||
| style="text-align:right" | 0.5 |
| style="text-align:right" | 0.5 |
||
| style="text-align:right" | |
| style="text-align:right" | - |
||
|- |
|- |
||
| style="text-align:left" | Tier 2 |
| style="text-align:left" | Tier 2 |
||
| style="text-align:right" | - |
| style="text-align:right" | - |
||
| style="text-align:right" | - |
| style="text-align:right" | - |
||
| style="text-align:right" | 2.4 |
|||
| style="text-align:right" | - |
| style="text-align:right" | - |
||
| style="text-align:right" | 0.5 |
|||
| style="text-align:right" | 2.0 |
| style="text-align:right" | 2.0 |
||
| style="text-align:right" | 0.7 |
| style="text-align:right" | 0.7 |
||
| style="text-align:right" | 6.4 |
| style="text-align:right" | 6.4 |
||
| style="text-align:right" | - |
| style="text-align:right" | - |
||
| style="text-align:right" | |
| style="text-align:right" | 0.7 |
||
|- |
|- |
||
| style="text-align:left" | Tier 1 |
| style="text-align:left" | Tier 1 |
||
| style="text-align:right" | 0.1 |
|||
| style="text-align:right" | - |
|||
| style="text-align:right" | - |
| style="text-align:right" | - |
||
| style="text-align:right" | 0.1 |
|||
| style="text-align:right" | 2.4 |
|||
| style="text-align:right" | 0.1 |
| style="text-align:right" | 0.1 |
||
| style="text-align:right" | - |
| style="text-align:right" | - |
||
| Line 1,369: | Line 1,361: | ||
| style="text-align:right" | 0.4 |
| style="text-align:right" | 0.4 |
||
| style="text-align:right" | - |
| style="text-align:right" | - |
||
| style="text-align:right" | |
| style="text-align:right" | 4.0 |
||
|} |
|} |
||
</div> |
</div> |
||
* o/w Grandfathered debt |
|||
==== o/w Grandfathered debt ==== |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id="t31" class="wikitable fintable" |
{| id="t31" class="wikitable fintable" |
||
|+ o/w Grandfathered debt |
|+ o/w Grandfathered debt |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
| Line 1,408: | Line 1,398: | ||
| style="text-align:right" | - |
| style="text-align:right" | - |
||
| style="text-align:right" | 0.7 |
| style="text-align:right" | 0.7 |
||
| style="text-align:right" | - |
|||
| style="text-align:right" | 0.2 |
| style="text-align:right" | 0.2 |
||
| style="text-align:right" | - |
|||
| style="text-align:right" | - |
| style="text-align:right" | - |
||
|} |
|} |
||
| Line 1,425: | Line 1,415: | ||
* FY25 Total General Account invested assets |
* FY25 Total General Account invested assets |
||
* Duration gap at -0.4 year |
* Duration gap at -0.4 year |
||
* Euro 450 billion |
|||
* Invested assets mix: |
|||
* Fixed income |
|||
* Real estate |
|||
* Infrastructure equity |
|||
* Listed equities |
|||
* Private equity and hedge funds |
|||
* Cash |
|||
* Policy loans |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id="t32" class="wikitable fintable" |
{| id="t32" class="wikitable fintable" |
||
|+ |
|+ FY25 Total General Account invested assets (Euro 450 billion) |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | Invested assets (100%)<br/>In Euro billion |
||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
! class="col-s" style="text-align:right" | % |
! class="col-s" style="text-align:right" | % |
||
| Line 1,483: | Line 1,464: | ||
| style="text-align:right" | 0% |
| style="text-align:right" | 0% |
||
|- |
|- |
||
| style="text-align:left" | Total Insurance Invested Assets {{fn ref|4|2=Please refer to the financial supplement for more details.}} |
|||
| style="text-align:right" | 450 |
|||
| style="text-align:right" | 100% |
|||
|} |
|} |
||
</div> |
</div> |
||
| Line 1,503: | Line 1,484: | ||
|+ Invested assets (100%) In Euro billion |
|+ Invested assets (100%) In Euro billion |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
! class="col-s" style="text-align:right" | % of total G/A{{fn ref|1|2=G/A: General Account}} portfolio |
! class="col-s" style="text-align:right" | % of total G/A{{fn ref|1|2=G/A: General Account}} portfolio |
||
! style="text-align: |
! class="col-s" style="text-align:right" | Comments |
||
|- |
|- |
||
| style="text-align:left" | Residential Mortgages |
| style="text-align:left" | Residential Mortgages |
||
| style="text-align:right" | 16 |
| style="text-align:right" | 16 |
||
| style="text-align:right" | 4% |
| style="text-align:right" | 4% |
||
| style="text-align:right" | |
|||
| style="text-align:left" | - €6bn Dutch mortgages, NHG guaranteed<br/>- €10bn self originated mortgages in Switzerland (56% LTV) and Germany (45% LTV) |
|||
|- |
|||
| style="text-align:left" | CLO & ABS |
|||
| style="text-align:right" | 25 |
|||
| style="text-align:right" | 6% |
|||
| style="text-align:left" | - 91% senior CLOs with circa 40% subordination (100% rated AAA-A and 92% rated AAA-AA) |
|||
|- |
|||
| style="text-align:left" | Infrastructure debt |
|||
| style="text-align:right" | 8 |
|||
| style="text-align:right" | 2% |
|||
| style="text-align:left" | - Skewed towards resilient industries (Telecom, Utilities, Transport) |
|||
|- |
|||
| style="text-align:left" | CRE debt |
|||
| style="text-align:right" | 8 |
|||
| style="text-align:right" | 2% |
|||
| style="text-align:left" | - Strong sector diversification (mainly logistics, residential and retail), mostly in Europe, and circa 60% LTV |
|||
|- |
|||
| style="text-align:left" | Mid-Market lending |
|||
| style="text-align:right" | 10 |
|||
| style="text-align:right" | 2% |
|||
| style="text-align:left" | - Strong diversification with €8m average ticket<br/>- Investments through SMAs with strict underwriting guidelines : senior secured, covenants, restrictions on asset sales and sector allocation |
|||
|- |
|||
| style="text-align:left" | Other |
|||
| style="text-align:right" | 2 |
|||
| style="text-align:right" | 0% |
|||
| style="text-align:left" | |
|||
|- |
|||
! style="text-align:left" | Total Structured and Private Credit Assets |
|||
! class="col-s" style="text-align:right" | 69 |
|||
! class="col-s" style="text-align:right" | 15% |
|||
! style="text-align:left" | o/w 54% participating |
|||
|} |
|} |
||
</div> |
</div> |
||
* €6bn Dutch mortgages, NHG guaranteed |
|||
* €10bn self originated mortgages in Switzerland (56% LTV) and Germany (45% LTV) |
|||
</td> |
|||
</tr> |
|||
<tr> |
|||
<td>CLO & ABS</td> |
|||
<td>25</td> |
|||
<td>6%</td> |
|||
<td>- 91% senior CLOs with circa 40% subordination (100% rated AAA-A and 92% rated AAA-AA)</td> |
|||
</tr> |
|||
<tr> |
|||
<td>Infrastructure debt</td> |
|||
<td>8</td> |
|||
<td>2%</td> |
|||
<td>- Skewed towards resilient industries (Telecom, Utilities, Transport)</td> |
|||
</tr> |
|||
<tr> |
|||
<td>CRE debt</td> |
|||
<td>8</td> |
|||
<td>2%</td> |
|||
<td>- Strong sector diversification (mainly logistics, residential and retail), mostly in Europe, and circa 60% LTV</td> |
|||
</tr> |
|||
<tr> |
|||
<td>Mid-Market lending</td> |
|||
<td>10</td> |
|||
<td>2%</td> |
|||
<td> |
|||
* Strong diversification with €8m average ticket |
|||
* Investments through SMAs with strict underwriting guidelines : senior secured, covenants, restrictions on asset sales and sector allocation |
|||
</td> |
|||
</tr> |
|||
<tr> |
|||
<td>Other</td> |
|||
<td>2</td> |
|||
<td>0%</td> |
|||
<td></td> |
|||
</tr> |
|||
<tr> |
|||
<td>Total Structured and Private Credit Assets</td> |
|||
<td>69</td> |
|||
<td>15%</td> |
|||
<td>o/w 54% participating</td> |
|||
</tr> |
|||
</table> |
|||
<div class="ed-fn-notes" style="display:none"> |
<div class="ed-fn-notes" style="display:none"> |
||
| Line 1,555: | Line 1,550: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id="t34" class="wikitable |
{| id="t34" class="wikitable" |
||
|+ Euro 57 billion |
|+ FY25 Fixed Income Reinvestment (Total: Euro 57 billion) |
||
|- |
|- |
||
| style="text-align:left" | Government bonds & related (32%) – Average rating: AA |
|||
! class="col-s" style="text-align:right" | Share |
|||
! class="col-s" style="text-align:right" | Average rating |
|||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | Investment grade credit (40%)- Average rating: A |
||
| style="text-align:right" | 32% |
|||
| style="text-align:right" | AA |
|||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | ABS/CLO/IG fund financing (21%) |
||
| style="text-align:right" | 40% |
|||
| style="text-align:right" | A |
|||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | Below investment grade credit (7%) |
||
| style="text-align:right" | 21% |
|||
| style="text-align:right" | |
|||
|- |
|||
| style="text-align:left" | Below investment grade credit |
|||
| style="text-align:right" | 7% |
|||
| style="text-align:right" | |
|||
|} |
|} |
||
</div> |
</div> |
||
| Line 1,584: | Line 1,567: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id="t35" class="wikitable fintable" |
{| id="t35" class="wikitable fintable" |
||
|+ FY25 Fixed Income Reinvestment Yield |
|||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | Category |
||
! class="col-s" style="text-align:right" | Yield |
! class="col-s" style="text-align:right" | Yield |
||
|- |
|- |
||
| Line 1,601: | Line 1,585: | ||
* Euro 57 billion fixed income invested at 3.9% |
* Euro 57 billion fixed income invested at 3.9% |
||
* Average duration of 9 years |
* Average duration of 9 years |
||
* Includes Euro 19.7 billion of Private & |
* Includes Euro 19.7 billion of Private & Structured Credit invested at 4.7% (CLOs, ABS, Infra & CRE debt, Fund financing and Private HY) |
||
* Gradual shift from alternative total return assets to Private & |
* Gradual shift from alternative total return assets to Private & Structured credit |
||
<div class="ed-fn-notes" style="display:none"> |
<div class="ed-fn-notes" style="display:none"> |
||
{{fn note|1=1|2=Government and Corporate bonds and related.}} |
{{fn note|1=1|2=Government and Corporate bonds and related.}} |
||
{{fn note|1=2|2=Private & |
{{fn note|1=2|2=Private & Structured credit (CLOs, ABS, Infra & CRE debt, Fund financing and Private hybrid).}} |
||
</div> |
</div> |
||
| Line 1,618: | Line 1,602: | ||
=== AXA XL Insurance – Large Commercial & Specialty business === |
=== AXA XL Insurance – Large Commercial & Specialty business === |
||
* Well diversified across lines of business and geographies |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
| Line 1,625: | Line 1,609: | ||
|- |
|- |
||
! style="text-align:left" | Line of business |
! style="text-align:left" | Line of business |
||
! class="col-s" style="text-align:right" | Share |
! class="col-s" style="text-align:right" | Share (%) |
||
|- |
|- |
||
| style="text-align:left" | Casualty |
| style="text-align:left" | Casualty |
||
| Line 1,646: | Line 1,630: | ||
|- |
|- |
||
! style="text-align:left" | Geography |
! style="text-align:left" | Geography |
||
! class="col-s" style="text-align:right" | Share |
! class="col-s" style="text-align:right" | Share (%) |
||
|- |
|- |
||
| style="text-align:left" | Americas |
| style="text-align:left" | Americas |
||
| Line 1,659: | Line 1,643: | ||
</div> |
</div> |
||
* Leading market positions across lines |
|||
* Top 3 globally |
* Top 3 globally |
||
* Multinational Programs{{fn ref|2|2=Source: McKinsey}} |
* Multinational Programs{{fn ref|2|2=Source: McKinsey}} |
||
| Line 1,666: | Line 1,649: | ||
* Fine Art & Specie{{fn ref|4|2=Source: Industry Research Biz (January 2026)}} |
* Fine Art & Specie{{fn ref|4|2=Source: Industry Research Biz (January 2026)}} |
||
* Managing the cycle to deliver consistent profitability |
|||
* Profitability vs. Ex-price growth (%) by line: |
|||
* Professional lines |
|||
* Profitability vs Ex-price growth (%) chart with bubbles for: Property, Specialty, Casualty, Professional lines |
|||
* Casualty |
|||
* Specialty |
|||
* Property |
|||
* (Note: Chart shows positive correlation between ex-price growth and profitability for these lines; specific numeric values not printed) |
|||
<div class="ed-fn-notes" style="display:none"> |
<div class="ed-fn-notes" style="display:none"> |
||
| Line 1,685: | Line 1,672: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id="t38" class="wikitable fintable" |
{| id="t38" class="wikitable fintable" |
||
|+ Claims reserves ratio |
|+ Claims reserves ratio |
||
|- |
|- |
||
! colspan="5" style="text-align:center" | IFRS4 |
! colspan="5" style="text-align:center" | IFRS4 |
||
| Line 1,717: | Line 1,704: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id="t39" class="wikitable fintable" |
{| id="t39" class="wikitable fintable" |
||
|+ Technical reserves ratio |
|+ Technical reserves ratio |
||
|- |
|- |
||
! colspan="5" style="text-align:center" | IFRS4 |
! colspan="5" style="text-align:center" | IFRS4 |
||
| Line 1,749: | Line 1,736: | ||
{{pdf page|39|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|39|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
=== P&C – 2026 Simplified Group Nat Cat Reinsurance Program |
=== P&C – 2026 Simplified Group Nat Cat Reinsurance Program{{fn ref|1|2=Excludes local reinsurance covers;}} === |
||
In Euro |
* In Euro |
||
* Insurance segment (occurrence protection) |
|||
* Reinsurance segment (illustrative) |
|||
* Alternative Capital & Cat Bonds |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id="t40" class="wikitable fintable" |
{| id="t40" class="wikitable fintable" |
||
|+ Insurance segment (occurrence protection) |
|||
|+ P&C | 2026 Simplified Group Nat Cat Reinsurance Program¹ (In Euro) |
|||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | Peril |
||
! class="col-s" style="text-align:right" | |
! class="col-s" style="text-align:right" | Capacity |
||
! class="col-s" style="text-align:right" | |
! class="col-s" style="text-align:right" | Retention |
||
! class="col-s" style="text-align:right" | Europe Earthquake |
|||
! class="col-s" style="text-align:right" | NA Hurricane |
|||
! class="col-s" style="text-align:right" | NA Earthquake |
|||
! class="col-s" style="text-align:right" | Per other perils³ |
|||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | EU Windstorm |
||
| style="text-align:right" | 4.0bn |
| style="text-align:right" | 4.0bn |
||
| style="text-align:right" | 600m |
|||
|- |
|||
| style="text-align:left" | Europe Flood |
|||
| style="text-align:right" | 2.1bn |
| style="text-align:right" | 2.1bn |
||
| style="text-align:right" | 450m |
|||
|- |
|||
| style="text-align:left" | Europe Earthquake |
|||
| style="text-align:right" | 2.1bn |
| style="text-align:right" | 2.1bn |
||
| style="text-align:right" | 400m |
|||
|- |
|||
| style="text-align:left" | NA Hurricane |
|||
| style="text-align:right" | 1.2bn |
| style="text-align:right" | 1.2bn |
||
| style="text-align:right" | 600m{{fn ref|2|2=Varying retention between MX and NA (400m MX, 600m NA);}} |
|||
|- |
|||
| style="text-align:left" | NA Earthquake |
|||
| style="text-align:right" | 1.2bn |
| style="text-align:right" | 1.2bn |
||
| style="text-align:right" | |
| style="text-align:right" | 600m{{fn ref|2|2=Varying retention between MX and NA (400m MX, 600m NA);}} |
||
|- |
|- |
||
| style="text-align:left" | Per other perils{{fn ref|3|2=Other perils include Turkey earthquake, Other Europe and NA perils, South America Earthquake as well as a series of other secondary perils. Capacity varies by peril type.}} |
|||
| style="text-align:left" | Retention |
|||
| style="text-align:right" | |
| style="text-align:right" | |
||
| style="text-align:right" | 450m |
|||
| style="text-align:right" | 400m |
|||
| style="text-align:right" | 600m² |
|||
| style="text-align:right" | 600m² |
|||
| style="text-align:right" | 400m |
| style="text-align:right" | 400m |
||
|} |
|} |
||
</div> |
</div> |
||
* Reinsurance segment (illustrative) |
|||
* Alternative Capital & Cat Bonds |
|||
* Stable retention levels maintained in 2026 as in 2025 |
* Stable retention levels maintained in 2026 as in 2025 |
||
<div class="ed-fn-notes" style="display:none"> |
<div class="ed-fn-notes" style="display:none"> |
||
{{fn note|1=1|2=Excludes local reinsurance covers}} |
{{fn note|1=1|2=Excludes local reinsurance covers;}} |
||
{{fn note|1=2|2=Varying retention between MX and NA (400m MX, 600m NA)}} |
{{fn note|1=2|2=Varying retention between MX and NA (400m MX, 600m NA);}} |
||
{{fn note|1=3|2=Other perils include Turkey earthquake, Other Europe and NA perils, South America Earthquake as well as a series of other secondary perils. Capacity varies by peril type.}} |
{{fn note|1=3|2=Other perils include Turkey earthquake, Other Europe and NA perils, South America Earthquake as well as a series of other secondary perils. Capacity varies by peril type.}} |
||
</div> |
</div> |
||
{{pdf page|40|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|40|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
=== P&C – AXA Group earnings deviation with different levels of Nat Cat cost{{fn ref|1|2=Natural catastrophe cost defined as Aggregate Exceedance Probability (AEP) of all natural perils worldwide, net of tax and reinsurance. Deviation is compared to a normalized level, which are costs associated with natural catastrophes expected in an average year (ca. 4.5 points of estimated FY25 GEP, undiscounted and net of reinsurance).}} in 2026 === |
=== P&C – AXA Group earnings deviation with different levels of Nat Cat cost{{fn ref|1|2=1. Natural catastrophe cost defined as Aggregate Exceedance Probability (AEP) of all natural perils worldwide, net of tax and reinsurance. Deviation is compared to a normalized level, which are costs associated with natural catastrophes expected in an average year (ca. 4.5 points of estimated FY25 GEP, undiscounted and net of reinsurance).}} in 2026 === |
||
* In Euro billion (net of reinsurance) |
* In Euro billion (net of reinsurance) |
||
==== Group underlying earnings deviation to average Nat Cat charges in 2026 ==== |
==== Group underlying earnings deviation to average Nat Cat charges in 2026 ==== |
||
* net of reinsurance, post-tax |
* net of reinsurance, post-tax |
||
* More severe years |
* More severe years: Negative deviation in ca. 40% of cases |
||
* |
* Less severe years: Positive deviation in ca. 60% of cases |
||
* Less severe years |
|||
* Positive deviation in ca. 60% of cases |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
| Line 1,812: | Line 1,798: | ||
|+ Group underlying earnings deviation to average Nat Cat charges in 2026 (net of reinsurance, post-tax) |
|+ Group underlying earnings deviation to average Nat Cat charges in 2026 (net of reinsurance, post-tax) |
||
|- |
|- |
||
! style="text-align:left" | Probability |
! style="text-align:left" | Probability (Percentile) |
||
! style="text-align:right" | Earnings |
! style="text-align:right" | Earnings Deviation |
||
|- |
|- |
||
| style="text-align:left" | 1/20y (95th) |
| style="text-align:left" | 1/20y (95th) |
||
| Line 1,839: | Line 1,825: | ||
==== Average Expected Nat Cat charges ==== |
==== Average Expected Nat Cat charges ==== |
||
* net of reinsurance, pre-tax |
* net of reinsurance, pre-tax |
||
| Line 1,850: | Line 1,835: | ||
! class="col-s" style="text-align:right" | 2026 |
! class="col-s" style="text-align:right" | 2026 |
||
|- |
|- |
||
| style="text-align:left" | Average Expected Nat Cat charges |
| style="text-align:left" | Average Expected Nat Cat charges (in Euro billion) |
||
| style="text-align:right" | 2.6 |
| style="text-align:right" | 2.6 |
||
| style="text-align:right" | 2.7 |
| style="text-align:right" | 2.7 |
||
| Line 1,861: | Line 1,846: | ||
<div class="ed-fn-notes" style="display:none"> |
<div class="ed-fn-notes" style="display:none"> |
||
{{fn note|1=1|2=Natural catastrophe cost defined as Aggregate Exceedance Probability (AEP) of all natural perils worldwide, net of tax and reinsurance. Deviation is compared to a normalized level, which are costs associated with natural catastrophes expected in an average year (ca. 4.5 points of estimated FY25 GEP, undiscounted and net of reinsurance).}} |
{{fn note|1=1|2=1. Natural catastrophe cost defined as Aggregate Exceedance Probability (AEP) of all natural perils worldwide, net of tax and reinsurance. Deviation is compared to a normalized level, which are costs associated with natural catastrophes expected in an average year (ca. 4.5 points of estimated FY25 GEP, undiscounted and net of reinsurance).}} |
||
</div> |
</div> |
||
| Line 1,872: | Line 1,857: | ||
{{pdf page|42|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|42|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
=== P&C – Margin Analysis === |
=== P&C – Margin Analysis === |
||
* Changes versus FY24 at constant FX. |
|||
==== Technical Result ==== |
==== Technical Result ==== |
||
==== In Euro million (pre-tax) ==== |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id="t43" class="wikitable fintable" |
{| id="t43" class="wikitable fintable" |
||
|+ |
|+ In Euro million (pre-tax) |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
| Line 1,931: | Line 1,912: | ||
|} |
|} |
||
</div> |
</div> |
||
* FY25 sensitivity to Current Accident Year discount rate changes{{fn ref|2|2=Parallel shift of the full-year average yield curve (average of monthly opening discount rates of 2025) used for discounting FY25 current accident year net reserve.}} |
|||
* +25bps: €+0.2bn |
|||
* -25bps: €-0.2bn |
|||
==== Financial Result ==== |
==== Financial Result ==== |
||
==== In Euro million (pre-tax) ==== |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id="t44" class="wikitable fintable" |
{| id="t44" class="wikitable fintable" |
||
|+ |
|+ In Euro million (pre-tax) |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
| Line 1,976: | Line 1,951: | ||
|} |
|} |
||
</div> |
</div> |
||
* 2026e Insurance Finance Expenses (pre-tax): ~ €-1.4bn |
|||
* Sensitivity of 2026e Insurance Finance Expenses to changes in 2025 current AY Discount |
|||
* +25bps: ~ €-50m |
|||
* -25bps: ~ €+50m |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
| Line 2,011: | Line 1,981: | ||
</div> |
</div> |
||
* FY25 sensitivity to Current Accident Year discount rate changes{{fn ref|2|2=Parallel shift of the full-year average yield curve (average of monthly opening discount rates of 2025) used for discounting FY25 current accident year net reserve.}} |
|||
* +25bps: €+0.2bn |
|||
* -25bps: €-0.2bn |
|||
* 2026e Insurance Finance Expenses (pre-tax): ~ €-1.4bn |
|||
* Sensitivity of 2026e Insurance Finance Expenses to changes in 2025 current AY Discount |
|||
* +25bps: ~ €-50m |
|||
* -25bps: ~ €+50m |
|||
* Changes versus FY24 at constant FX. |
|||
<div class="ed-fn-notes" style="display:none"> |
<div class="ed-fn-notes" style="display:none"> |
||
{{fn note|1=1|2=Reinvestment yield on fixed income assets.}} |
{{fn note|1=1|2=Reinvestment yield on fixed income assets.}} |
||
| Line 2,018: | Line 1,997: | ||
{{pdf page|43|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|43|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
=== L&H – Margin Analysis === |
=== L&H – Margin Analysis === |
||
* Includes scope impact |
* Includes scope impact |
||
==== Technical Result ==== |
==== Technical Result ==== |
||
*In Euro million, pre-tax* |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id="t46" class="wikitable fintable" |
{| id="t46" class="wikitable fintable" |
||
|+ In Euro million, pre-tax |
|||
|+ Short-term Technical Margin |
|||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
| Line 2,042: | Line 2,020: | ||
| style="text-align:right" | 97.2% |
| style="text-align:right" | 97.2% |
||
| style="text-align:right" | -0.1pts |
| style="text-align:right" | -0.1pts |
||
|} |
|||
</div> |
|||
* Incl. recapture of Laya |
|||
<div style="overflow-x:auto"> |
|||
{| id="t47" class="wikitable fintable" |
|||
|+ Long-term Technical Margin |
|||
|- |
|||
! style="text-align:left" | |
|||
! class="col-s" style="text-align:right" | FY25 |
|||
! class="col-s" style="text-align:right" | Change |
|||
|- |
|- |
||
| style="text-align:left" | Long-term Technical Margin |
| style="text-align:left" | Long-term Technical Margin |
||
| Line 2,069: | Line 2,035: | ||
</div> |
</div> |
||
* Incl. recapture of Laya |
|||
==== Financial Result ==== |
|||
*In Euro million, pre-tax* |
|||
==== Financial Result ==== |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t47" class="wikitable fintable" |
||
|+ In Euro million, pre-tax |
|||
|+ Investment Income (non-VFA only) |
|||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
| Line 2,095: | Line 2,061: | ||
| style="text-align:right" | 3.8% |
| style="text-align:right" | 3.8% |
||
| style="text-align:right" | |
| style="text-align:right" | |
||
|} |
|||
</div> |
|||
<div style="overflow-x:auto"> |
|||
{| id="t49" class="wikitable fintable" |
|||
|+ Insurance Finance Expenses (non-VFA only) |
|||
|- |
|||
! style="text-align:left" | |
|||
! class="col-s" style="text-align:right" | FY25 |
|||
! class="col-s" style="text-align:right" | Change |
|||
|- |
|- |
||
| style="text-align:left" | Insurance Finance Expenses (non-VFA only) |
| style="text-align:left" | Insurance Finance Expenses (non-VFA only) |
||
| Line 2,121: | Line 2,077: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t48" class="wikitable fintable" |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
| Line 2,149: | Line 2,105: | ||
</div> |
</div> |
||
==== Life & |
==== Life & Health FY25 CSM Key Sensitivities ==== |
||
*(in Euro billion)* |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t49" class="wikitable fintable" |
||
|+ (in Euro billion) |
|||
|- |
|||
! style="text-align:left" | |
|||
! class="col-s" style="text-align:right" | |
|||
|- |
|- |
||
| style="text-align:left" | Baseline |
| style="text-align:left" | Baseline |
||
| Line 2,190: | Line 2,142: | ||
{{fn note|1=1|2=Reinvestment yield on fixed income assets.}} |
{{fn note|1=1|2=Reinvestment yield on fixed income assets.}} |
||
</div> |
</div> |
||
* Changes versus FY24 at constant FX. |
|||
{{pdf page|44|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|44|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
| Line 2,200: | Line 2,150: | ||
{{pdf page|45|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|45|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
=== Expanding |
=== Expanding AXA’s role in society: AXA for Progress Index{{fn ref|1|2=AXA’s Sustainability Statement is subject to completion of a certification with limited assurance by AXA Group’s auditors and will be presented to the AXA Board of Directors for approval on March 11, 2026.}} === |
||
==== As a GLOBAL INVESTOR ==== |
==== As a GLOBAL INVESTOR ==== |
||
* Target |
|||
<div style="overflow-x:auto"> |
|||
* €5bn{{fn ref|2|2=Scope: corporate and sovereign debt, real estate and private assets. Timeframe: per annum through 2030.}} in climate transition financing per year |
|||
{| id="t50" class="wikitable" |
|||
* >€500m{{fn ref|2|2=Scope: corporate and sovereign debt, real estate and private assets. Timeframe: per annum through 2030.}} in community resilience financing per year |
|||
|- |
|||
* 2025 Result |
|||
! style="text-align:left" | Target |
|||
* €6.4bn |
|||
! style="text-align:right" | 2025 Result |
|||
* €1.4bn |
|||
|- |
|||
| style="text-align:left" | €5bn{{fn ref|2|2=Scope: corporate and sovereign debt, real estate and private assets. Timeframe: per annum through 2030.}} in climate transition financing per year |
|||
| style="text-align:right" | €6.4bn |
|||
|- |
|||
| style="text-align:left" | >€500m{{fn ref|2|2=Scope: corporate and sovereign debt, real estate and private assets. Timeframe: per annum through 2030.}} in community resilience financing per year |
|||
| style="text-align:right" | €1.4bn |
|||
|} |
|||
</div> |
|||
==== As a GLOBAL INSURER ==== |
==== As a GLOBAL INSURER ==== |
||
* Target |
|||
<div style="overflow-x:auto"> |
|||
* €6bn{{fn ref|3|2=Scope: AXA France, AXA Germany, AXA Switzerland, AXA UK & Ireland, AXA Belgium, AXA Hong Kong, AXA Mexico, and AXA XL; Unit: Gross Written Premiums (GWP); Timeframe: cumulative 2024-2026.}} in P&C GWP to support transition underwriting (cumulative 2024-2026) |
|||
{| id="t51" class="wikitable" |
|||
* >20,000{{fn ref|4|2=Scope: Commercial lines portfolio of AXA France, AXA Germany, AXA Switzerland, AXA UK, AXA Belgium, AXA Hong Kong, AXA Mexico, and AXA XL; Climate solutions & services include (i) training/education, (ii) risk assessment/awareness, (iii) gap analysis, (iv) prevention/adaptation solution, and/or (v) crisis management/remediation response. Timeframe: cumulative 2024-2026. Following strong support within the Group for climate adaption solutions & services in 2024 and 2025, AXA is proposing a significant increase in its target for the 2024-2026 period, from >9,000 to >20,000.}} climate adaptation solutions & services (cumulative 2024-2026) *Target revised in 2025* |
|||
|- |
|||
* >20m{{fn ref|5|2=Low-income to mass market segments in emerging markets and modest income segments in mature markets.}} inclusive insurance customers by 2026 |
|||
! style="text-align:left" | Target |
|||
* 2025 Result |
|||
! style="text-align:right" | 2025 Result |
|||
* €4.6bn |
|||
|- |
|||
* 19,698 Cumulative 2024-2025 |
|||
| style="text-align:left" | €6bn{{fn ref|3|2=Scope: AXA France, AXA Germany, AXA Switzerland, AXA UK & Ireland, AXA Belgium, AXA Hong Kong, AXA Mexico, and AXA XL; Unit: Gross Written Premiums (GWP); Timeframe: cumulative 2024-2026.}} in P&C GWP to support transition underwriting (cumulative 2024-2026) |
|||
* 20.6m |
|||
| style="text-align:right" | €4.6bn |
|||
|- |
|||
| style="text-align:left" | >20,000{{fn ref|4|2=Scope: Commercial lines portfolio of AXA France, AXA Germany, AXA Switzerland, AXA UK, AXA Belgium, AXA Hong Kong, AXA Mexico, and AXA XL; Climate solutions & services include (i) training/education, (ii) risk assessment/awareness, (iii) gap analysis, (iv) prevention/adaptation solution, and/or (v) crisis management/remediation response. Timeframe: cumulative 2024-2026. Following strong support within the Group for climate adaption solutions & services in 2024 and 2025, AXA is proposing a significant increase in its target for the 2024-2026 period, from >9,000 to >20,000.}} climate adaptation solutions & services (cumulative 2024-2026) Target revised in 2025 |
|||
| style="text-align:right" | 19,698 Cumulative 2024-2025 |
|||
|- |
|||
| style="text-align:left" | >20m{{fn ref|5|2=Low-income to mass market segments in emerging markets and modest income segments in mature markets.}} inclusive insurance customers by 2026 |
|||
| style="text-align:right" | 20.6m |
|||
|} |
|||
</div> |
|||
==== As a COMPANY ==== |
==== As a COMPANY ==== |
||
* Target |
|||
<div style="overflow-x:auto"> |
|||
* >80,000{{fn ref|6|2=Number of employees who have been trained on climate change adaptation, completing a training under the AXA Sustainability Academy. Timeframe: cumulative 2024-2026.}} AXA Group employees trained on climate adaptation by 2026 |
|||
{| id="t52" class="wikitable fintable" |
|||
* Contribute to Net-Zero -50%{{fn ref|7|2=Variation of AXA Group absolute carbon emissions (scope: energy Scopes 1 and 2, car fleet and business travel). Timeframe: 2019-2030.}} by 2030 in absolute carbon emissions and offset of residual emissions{{fn ref|8|2=Carbon credits from projects that focus on capturing and storing carbon emissions from the atmosphere using nature-based or technical solutions (e.g. restorative agriculture, forest restoration or carbon capture and storage).}} |
|||
|- |
|||
* 50% Percentage of AXA Group employees engaged in volunteering activities by 2026 |
|||
! style="text-align:left" | Target |
|||
* 2025 Result |
|||
! class="col-m" style="text-align:right" | 2025 Result |
|||
* 46,420 |
|||
|- |
|||
* -64% Reduction against 2019 |
|||
| style="text-align:left" | >80,000{{fn ref|6|2=Number of employees who have been trained on climate change adaptation, completing a training under the AXA Sustainability Academy. Timeframe: cumulative 2024-2026.}} AXA Group employees trained on climate adaptation by 2026 |
|||
* 56% |
|||
| style="text-align:right" | 46,420 |
|||
|- |
|||
| style="text-align:left" | Contribute to Net-Zero -50%{{fn ref|7|2=Variation of AXA Group absolute carbon emissions (scope: energy Scopes 1 and 2, car fleet and business travel). Timeframe: 2019-2030.}} by 2030 in absolute carbon emissions and offset of residual emissions{{fn ref|8|2=Carbon credits from projects that focus on capturing and storing carbon emissions from the atmosphere using nature-based or technical solutions (e.g. restorative agriculture, forest restoration or carbon capture and storage).}} |
|||
| style="text-align:right" | -64% Reduction against 2019 |
|||
|- |
|||
| style="text-align:left" | 50% Percentage of AXA Group employees engaged in volunteering activities by 2026 |
|||
| style="text-align:right" | 56% |
|||
|} |
|||
</div> |
|||
<div class="ed-fn-notes" style="display:none"> |
<div class="ed-fn-notes" style="display:none"> |
||
{{fn note|1=1|2= |
{{fn note|1=1|2=AXA’s Sustainability Statement is subject to completion of a certification with limited assurance by AXA Group’s auditors and will be presented to the AXA Board of Directors for approval on March 11, 2026.}} |
||
{{fn note|1=2|2=Scope: corporate and sovereign debt, real estate and private assets. Timeframe: per annum through 2030.}} |
{{fn note|1=2|2=Scope: corporate and sovereign debt, real estate and private assets. Timeframe: per annum through 2030.}} |
||
{{fn note|1=3|2=Scope: AXA France, AXA Germany, AXA Switzerland, AXA UK & Ireland, AXA Belgium, AXA Hong Kong, AXA Mexico, and AXA XL; Unit: Gross Written Premiums (GWP); Timeframe: cumulative 2024-2026.}} |
{{fn note|1=3|2=Scope: AXA France, AXA Germany, AXA Switzerland, AXA UK & Ireland, AXA Belgium, AXA Hong Kong, AXA Mexico, and AXA XL; Unit: Gross Written Premiums (GWP); Timeframe: cumulative 2024-2026.}} |
||
{{fn note|1=4|2=Scope: Commercial lines portfolio of AXA France, AXA Germany, AXA Switzerland, AXA UK, AXA Belgium, AXA Hong Kong, AXA Mexico, and AXA XL; Climate solutions & services include (i) training/education, (ii) risk assessment/awareness, (iii) gap analysis, (iv) prevention/adaptation solution, and/or (v) crisis management/remediation response. Timeframe: cumulative 2024-2026. Following strong support within the Group for climate adaption solutions & services in 2024 and 2025, AXA is proposing a significant increase in its target for the 2024-2026 period, from >9,000 to >20,000.}} |
{{fn note|1=4|2=Scope: Commercial lines portfolio of AXA France, AXA Germany, AXA Switzerland, AXA UK, AXA Belgium, AXA Hong Kong, AXA Mexico, and AXA XL; Climate solutions & services include (i) training/education, (ii) risk assessment/awareness, (iii) gap analysis, (iv) prevention/adaptation solution, and/or (v) crisis management/remediation response. Timeframe: cumulative 2024-2026. Following strong support within the Group for climate adaption solutions & services in 2024 and 2025, AXA is proposing a significant increase in its target for the 2024-2026 period, from >9,000 to >20,000.}} |
||
{{fn note|1=5|2=Low-income to mass market segments in emerging markets and modest income segments in mature markets.}} |
{{fn note|1=5|2=Low-income to mass market segments in emerging markets and modest income segments in mature markets.}} |
||
{{fn note|1=6|2=Number of employees who have been trained on climate change adaptation, completing a training under the AXA Sustainability Academy. Timeframe: cumulative 2024-2026.}} |
{{fn note|1=6|2=Number of employees who have been trained on climate change adaptation, completing a training under the AXA Sustainability Academy. Timeframe: cumulative 2024-2026.}} |
||
| Line 2,244: | Line 2,220: | ||
=== Sustainability Performance & Ratings === |
=== Sustainability Performance & Ratings === |
||
* S&P Global |
|||
* S&P Global: 2025 percentile: 97th {{fn ref|1|2=The CSA ranking is a key performance indicator for AXA Group, used to calculate the grant of Long-Term Incentives (more precisely AXA Restricted Shares). Results as of February 6th, 2026.}} in Dow Jones Best-in-Class Europe & World indices |
|||
* 2025 percentile: 97th {{fn ref|1|2=The CSA ranking is a key performance indicator for AXA Group, used to calculate the grant of Long-Term Incentives (more precisely AXA Restricted Shares). Results as of February 6th, 2026.}} in Dow Jones Best-in-Class Europe & World indices |
|||
* MSCI: 2025 score: AAA |
|||
* MSCI |
|||
* CDP: 2025 score: B |
|||
* 2025 score: AAA |
|||
* MORNINGSTAR SUSTAINALYTICS: 2025 ESG Risk Rating: 17.0– Low risk |
|||
* CDP |
|||
* FTSE RUSSELL An LSEG Business: 2025 score: 4.3/5 in FTSE4Good Index Series |
|||
* 2025 score: B |
|||
* MORNINGSTAR SUSTAINALYTICS |
|||
* 2025 ESG Risk Rating: 17.0– Low risk |
|||
* FTSE RUSSELL An LSEG Business |
|||
* 2025 score: 4.3/5 in FTSE4Good Index Series |
|||
<div class="ed-fn-notes" style="display:none"> |
<div class="ed-fn-notes" style="display:none"> |
||
| Line 2,263: | Line 2,244: | ||
* Transversal & Other: includes AXA Assistance, AXA Liabilities Managers, AXA and other Central Holdings. |
* Transversal & Other: includes AXA Assistance, AXA Liabilities Managers, AXA and other Central Holdings. |
||
* AXA Investment Managers (until July 1, 2025): includes AXA Investment Managers, Select (previously referred to as Architas) and Capza which are fully consolidated and Asian joint ventures which are consolidated under the equity method. |
* AXA Investment Managers (until July 1, 2025): includes AXA Investment Managers, Select (previously referred to as Architas) and Capza which are fully consolidated and Asian joint ventures which are consolidated under the equity method. |
||
* Unless otherwise specified herein, all comparative figures for going back to 2023 are under the IFRS17/9 accounting standards that became effective on January 1, 2023. Figures for financial periods prior to 2023 have not been restated under IFRS17/9 and are presented under IFRS4, the applicable accounting standard that preceded the implementation of IFRS17/9 |
* Unless otherwise specified herein, all comparative figures for going back to 2023 are under the IFRS17/9 accounting standards that became effective on January 1, 2023. Figures for financial periods prior to 2023 have not been restated under IFRS17/9 and are presented under IFRS4, the applicable accounting standard that preceded the implementation of IFRS17/9 |
||
Revision as of 23:01, 22 July 2026
| Document info | |
|---|---|
| Document ID | snjra2xp9r |
| Organization | AXA |
| Year | 2025 |
| Period | FY |
| Period label | FY25 |
| Document category | Earnings presentation |
| Document name | AXA Full Year 2025 Results Presentation |
| Publication date | 2026-02-26 |
| Language | English |
| Pages | 49 |
| Source | original URL |
| Summary | wiki page |
Full Year 2025 Earnings Presentation
IMPORTANT LEGAL INFORMATION AND CAUTIONARY STATEMENTS CONCERNING FORWARD-LOOKING STATEMENTS AND THE USE OF NON-GAAP FINANCIAL MEASURES
- Certain statements contained herein may be forward-looking statements including, but not limited to, statements that are predictions of or indicate future events, trends, plans, expectations or objectives, and other information that is not historical information. Forward-looking statements are generally identified by words and expressions such as “expects”, “anticipates”, “may”, “plan,” “target” or any variations or similar terminology of these words and expressions, or conditional verbs such as, without limitations, “would” and “could”. In particular, the statements in this presentation regarding expected underlying earnings per share (“UEPS”) growth for 2026 are forward-looking statements to provide one-off guidance in the context of the last year of the Group’s current strategic plan. These statements in this presentation are based on Management’s current views and intentions and are subject to change. Undue reliance should not be placed on forward-looking statements because, by their nature, they are subject to known and unknown risks and uncertainties, many of which are outside AXA’s control, and can be affected by other factors that could cause AXA’s actual results to differ materially from those expressed in, or implied or projected by, such forward-looking statements. Each forward-looking statement speaks only at the date of this presentation. Please refer to Part 5 - “Risk Factors and Risk Management” of AXA’s Universal Registration Document for the year ended December 31, 2024 (the “2024 Universal Registration Document”) for a description of certain important factors, risks and uncertainties that may affect AXA’s business and/or results of operations. AXA specifically disclaims and undertakes no obligation to publicly update or revise any of these forward-looking statements, whether to reflect new information, future events or circumstances or otherwise, except as required by applicable laws and regulations.
- In addition, this presentation refers to certain non-GAAP financial measures, or alternative performance measures (“APMs”), used by Management in analyzing AXA’s operating trends, financial performance and financial position and providing investors with additional information that Management believes to be useful and relevant regarding AXA’s results. These non-GAAP financial measures generally have no standardized meaning and therefore may not be comparable to similarly labelled measures used by other companies. As a result, none of these non-GAAP financial measures should be considered in isolation from, or as a substitute for, the Group’s consolidated financial statements and related notes prepared in accordance with IFRS. “Underlying earnings”, UEPS (“underlying earnings per share”), “underlying return on equity”, “combined ratio” and “debt gearing” are APMs as defined in ESMA’s guidelines and the AMF’s related position statement issued in 2015. AXA provides a reconciliation of such APMs to the most closely related line item, subtotal, or total in the financial statements of the corresponding period (and/or their calculation methodology, as applicable) in its Activity Report as of December 31, 2025 (“AXA’s 2025 Activity Report”), on the pages indicated under the heading “USE OF NON-GAAP AND ALTERNATIVE PERFORMANCE MEASURES”. For further information on the above-mentioned and other non-GAAP financial measures used in this presentation, see the Glossary in AXA’s 2025 Activity Report.
- AXA’s Activity Report as of December 31, 2025 is available on the AXA Group website (www.axa.com).
- AXA’s consolidated financial statements for the year ended December 31, 2025 were examined by the Board of Directors on February 25, 2026, and are subject to completion of an audit procedure by AXA’s statutory auditors.
Contents
- 1. FY25 Highlights p.04
- Thomas Buberl, Group CEO
- 2. FY25 Business Performance p.09
- Guillaume Borie, Global Head of Finance, Strategy, Underwriting, Risk, and Technology
- 3. FY25 Financial Performance p.13
- Alban de Mailly Nesle, Group CFO
FY25 Highlights
- Thomas Buberl, Group CEO
Full Year 2025 – Excellent performance
- +6% Revenues vs. FY24
- +8% Underlying EPS vs. FY24
- 16% ROE FY25
- 224% Solvency II ratio FY25
- Delivering value for shareholders +8% DPS1(footnote: Based on the dividend proposed by AXA’s Board of Directors on February 25, 2026 and subject to approval by the Shareholders’ Annual General Meeting to be held on April 30, 2026.) growth and €1.25bn annual share buy back2(footnote: Following AXA’s Board of Directors’ approval on February 25, 2026, and expected to commence as soon as reasonably practicable, subject to market conditions.)
- Confident to deliver underlying EPS growth at the upper end of 6%-8% target range for 2026
Executing the plan on growth, margin and efficiency
| Period | Underlying earnings | Change |
|---|---|---|
| FY24 | 8.1 | |
| FY25 | 8.4 | +6% |
| FY25 excluding AXA IM | +9% |
- High organic growth: +6% top line growth, well balanced across lines (P&C: +5%, Life: +9%, Health: +5%)
- Record profitability: Further margin expansion in P&C and L&H; improvement in efficiency
- Scaling the business: Continued investments in growth and technology
- Consistent earnings growth while enhancing reserve prudence
Diversified franchise, well positioned in an attractive industry
Secular trends fueling demand across businesses
- Protection gaps and emerging corporate risks
- Demographics driving demand for private retirement and healthcare
| Business Segment | Share (%) |
|---|---|
| Life | 33% |
| Health | 17% |
| Large & Specialty | 17% |
| SME & Mid-market | 16% |
| Retail | 17% |
Our right to win
- Leading brand & high customer NPS
- Strong and diversified distribution
- Technical expertise to price & underwrite risks
- Scale offering cost advantage
Laying the foundation for the next plan
- Clear tech and AI roadmap
- Driving efficiency
- Enhancing capital allocation discipline
- Building resilience
- Confidence in sustaining earnings growth
FY25 Business Performance
- Guillaume Borie
- Global Head of Finance, Strategy, Underwriting, Risk, and Technology
Strong delivery across our businesses
- Change for Gross written premiums at constant scope and FX and for underlying earnings at constant FX.
| Gross written premiums | Underlying earnings | |
|---|---|---|
| France (27% of total GWP1(footnote: FY25 gross written premiums excluding AXA IM, Holdings, AXA Assistance, and AXA Liabilities Managers.)) | +6% to €31bn | +7% to €2.2bn |
| Europe (38% of total GWP1(footnote: FY25 gross written premiums excluding AXA IM, Holdings, AXA Assistance, and AXA Liabilities Managers.)) | +6% to €43bn | +9% to €3.5bn |
| AXA XL (17% of total GWP1(footnote: FY25 gross written premiums excluding AXA IM, Holdings, AXA Assistance, and AXA Liabilities Managers.)) | +4% to €19bn | +9% to €1.9bn |
| Asia, Africa & EME-LATAM (18% of total GWP1(footnote: FY25 gross written premiums excluding AXA IM, Holdings, AXA Assistance, and AXA Liabilities Managers.)) | +13% to €20bn | +6% to €1.5bn |
P&C – Strong margins, confidence in sustaining growth
- €58bn GWP
- GWP mix: Retail, SME & Mid-market, AXA XL1(footnote: Includes AXA XL Re premiums of €2.6bn.) (Large & Specialty) — shares not printed
- Underlying earnings +9%2(footnote: Change FY25 vs. FY24 at constant FX.) to €5.9bn
2025 and Beyond 2025 Strategy
- Retail and SME & Mid-market
- 2025: Growing volumes while expanding margins
- Beyond 2025: Investing to improve customer retention & expanding distribution footprint
- AXA XL (Large & Specialty)
- 2025: Profitable growth with stable margins
- Beyond 2025: Capitalizing on attractive growth opportunities and continued cycle management
Key Drivers
- Continued progress on efficiency
- Higher investment income
- Data & AI to further enhance customer experience & technical excellence
L&H – Good momentum, well positioned to capture growth opportunities
- €57bn GWP
- GWP mix:
- Short-term
- Long-term
- Underlying earnings +7%1(footnote: 1. Change FY25 vs. FY24 at constant FX.) to €3.5bn
Strategic Roadmap
| 2025 | Beyond 2025 | |
|---|---|---|
| Long-term business | Accelerating net flows in Savings at attractive margins | Capturing savings & retirement opportunity, sourcing best asset management products for our customers |
| Short-term business | Growing technical results while absorbing Mexico VAT impact | Capitalizing on demand for health & protection while further improving our margins |
- Focus on cost reduction
- Increasing penetration of Protection riders in Savings offerings
- Leveraging AI to reduce claims leakage & improve customer outcomes in Health
FY25 Financial Performance
- Alban de Mailly Nesle
- Group CFO
P&C – Continued disciplined growth
- In Euro billion
GWP & Other Revenues
| FY24 | FY25 | Change | o/w pricing1(footnote: Price effect.) | o/w volume2(footnote: Includes exposure adjustments and mix & other effects.) | |
|---|---|---|---|---|---|
| Commercial lines | 35.8 | +4% | +2% | +2% | |
| AXA XL Reinsurance | 2.6 | +8% | +0.3% | +7% | |
| Retail lines | 19.7 | +7% | +5% | +2% | |
| Total | 56.5 | 58.0 | +5% |
- Continued pricing momentum and volume growth in Mid-market and SME
- Growing in lines of business with attractive margins while remaining focused on retention at AXA XL Insurance
- Growth supported by alternative capital
- Favorable pricing trends and strong growth in net new contracts (+1.7m in FY25)
P&C – Delivering further margin expansion while enhancing reserve prudence
Combined ratio
| FY24 | FY25 | |
|---|---|---|
| Undiscounted CY loss ratio (ex Nat Cat) | 67.4% | 67.0% |
| Expense ratio | 25.0% | 24.8% |
| Nat Cat | 3.8% | 3.4% |
| Prior year reserve development | -1.6% | -1.1% |
| Discount | -3.6% | -3.5% |
| Total Combined ratio | 91.0% | 90.6% |
- Better undiscounted current year loss ratio excluding Nat Cat from:
- Margin expansion in Commercial lines SME & mid-market business and Personal lines reflecting favorable pricing environment
- Stable AXA XL Insurance margins at attractive levels reflecting disciplined cycle management
- Improvement in expense ratio reflecting the impact of efficiency measures, while continuing to invest in growth initiatives and technology
- Nat Cat charges below normalized load
- Lower reliance on prior year reserve development
- Taking advantage of a good year to enhance reserve prudence
P&C – Earnings growth from higher underwriting and financial result
- In Euro million
| Driver | Value |
|---|---|
| FY24 | 5,510 |
| Volume growth 1(footnote: Underwriting result includes expenses.) | +292 |
| Margin improvement 1(footnote: Underwriting result includes expenses.) | +189 |
| Investment income (Financial result) | +435 |
| Insurance finance expenses (Financial result) | -235 |
| Tax | -169 |
| Affiliates, FX & other | -150 |
| FY25 | 5,872 |
| Total Change at constant FX | +9% |
- Better underwriting result from strong volume growth and improved all-year combined ratio while enhancing reserve prudence
- Increase in investment income reflecting higher volumes and better reinvestment yields on fixed income assets
- Higher unwind of discount of claims reserves, in line with guidance
- Unfavorable forex impact notably due to USD depreciation vs. EUR
- Change at constant FX.
- In Euro billion
| FY24 | FY25 | Change | |
|---|---|---|---|
| Protection | 17.3 | +11% | |
| Unit-linked | 9.3 | +13% | |
| Capital light G/A | 9.0 | +7% | |
| Traditional G/A | 1.9 | -7% | |
| Total | 34.5 | 37.5 | +9% |
| FY24 | FY25 | Change | |
|---|---|---|---|
| Individual | 10.5 | +6% | |
| Group | 8.5 | +4% | |
| Total | 17.5 | 19.0 | +5% |
- o/w FY25 Employee Benefits1(footnote: Including both short-term and long-term Employee Benefits GWP and other revenues.) Euro 12.9 billion (+4% vs. FY24)
| Protection | +4.9 |
| Health | +2.7 |
| Unit-Linked | +1.5 |
| Capital light G/A | +1.2 |
| Traditional G/A | -5.0 |
- Change at constant scope and FX.
Life & Health – Strong volume growth in Savings and Protection impacted by higher interest rates on discounting
- In Euro billion
- PVEP was impacted by higher interest rates on discounting despite strong growth in Life volumes
- NB CSM was driven by robust Savings & Protection sales, with reported growth impacted by higher interest rates for discounting of future profits
- NBV was broadly stable as strong growth in NB CSM balanced lower contribution from short-term multinational business in France
| FY24 | FY25 | Change at constant scope and FX | |
|---|---|---|---|
| Protection & Health | 31.4 | -4% | |
| Unit-Linked | 8.5 | +18% | |
| Capital-light G/A | 7.8 | -10% | |
| Traditional G/A | 1.7 | -10% | |
| Total PVEP | 50.9 | 49.4 | -2% |
| FY24 | FY25 | Change at constant scope and FX | |
|---|---|---|---|
| NB CSM (pre-tax) | 2.2 | 2.2 | +3% |
| FY24 | FY25 | Change at constant scope and FX | |
|---|---|---|---|
| NBV (post-tax) | 2.3 | 2.2 | stable |
| NBV margin | 4.4% | 4.5% |
- Change at constant scope and FX.
Life & Health – Growth in new business driving Normalized CSM growth
- In Euro billion
- Normalized CSM growth +2%
- Normalized CSM up by +2%, with CSM release growth reflecting better margins and new business CSM growth impacted by higher rates
- Economic variance reflecting government spreads tightening and positive equity market returns
- Operating variance driven by better margins and net flows that were more than offset by a reduction in the duration of Group Life business in Switzerland
- FX impact mainly from JPY and HKD depreciation
Contractual Service Margin rollforward
| Item | Value |
|---|---|
| FY24 | 33.6 |
| New business CSM | +2.2 |
| Underlying return on in-force | +1.3 |
| CSM release | -3.0 |
| Economic variance | +0.6 |
| Operating variance | -0.3 |
| Affiliates, FX & other | -1.4 |
| FY25 | 33.0 |
| Segment | FY24 | FY25 |
|---|---|---|
| o/w Life | 25.8 | 25.4 |
| o/w Health | 7.7 | 7.6 |
- Change at constant scope and FX.
Life & Health – Strong momentum in both short-term and long-term business
| Component | FY24 | Bridge | FY25 |
|---|---|---|---|
| Short-term technical margin | 415 | +60 | 479 |
| Long-term result incl. CSM release | 2,680 | +156 | 2,804 |
| Financial result | 975 | -11 | 946 |
| Tax & others / Tax, FX and others | -748 | -27 | -728 |
| Total Underlying Earnings | 3,323 | +7%*(footnote: Change at constant FX.) | 3,501 |
| Metric | FY24 | FY25 | Change vs. FY24*(footnote: Change at constant FX.) |
|---|---|---|---|
| o/w Life | 2.6 | 2.7 | +4% |
| o/w Health | 0.7 | 0.8 | +17% |
- Strong short-term technical margin reflecting underwriting and claims initiatives that more than offset the impact of legislative change on the recoverability of value added tax in Mexico (€-0.1bn)
- Higher long-term results from increase in CSM release (+8%) reflecting growth in reserve base, including from favorable equity market performance, and better margins
Growth in net income reflecting higher earnings & the gain from the sale of AXA IM
| FY24 | FY25 | Change | |
|---|---|---|---|
| Property & Casualty | 5.5 | 5.9 | +9% |
| Life & Health | 3.3 | 3.5 | +7% |
| Asset Management | 0.4 | 0.2 | -57% |
| Holdings & other | -1.2 | -1.2 | - |
| Underlying earnings | 8.1 | 8.4 | +6% |
| Non-financial flows | -0.5 | +2.1 | |
| o/w capital gains from AXA IM disposal | - | +2.2 | |
| Financial flows (incl. RCG) | +0.3 | -0.7 | |
| Net income | 7.9 | 9.8 | +26% |
| FY24 | FY25 | Change | |
|---|---|---|---|
| Underlying earnings per share | 3.59 | 3.86 | +8% |
- +6% from earnings growth
- +3% from capital management
- -2% from forex
- including -1% from temporary earnings dilution from AXA IM sale due to the timing of anti-dilutive share buyback
- Underlying earnings
- Strong performance from insurance businesses
- Stable holding cost, expected to remain at current level in 2026
- Net Income
- Higher net income mainly reflecting higher underlying earnings and the gain from the sale of AXA IM
- Lower financial flows reflecting unfavorable forex impact
- Change at constant FX for underlying earnings and net income. Change on reported basis for underlying earnings per share.
- In Euro billion
| FY24 | HY25 | FY25 | |
|---|---|---|---|
| Total Shareholders' equity | 49.9 | 45.5 | 47.2 |
| SHE (excl. OCI) | 58.0 | 52.7 | 54.0 |
| Net OCI | -8.1 | -7.2 | -6.8 |
| SHE (excl. OCI & undated subordinated debt) | 53.2 | 47.0 | 49.4 |
| Debt gearing | 20.6% | 23.4% | 22.3% |
| Underlying ROE | 15.2% | 17.5% | 16.0% |
| FY24 to FY25 | HY25 to FY25 | |
|---|---|---|
| Opening Shareholders' equity | 49.9 | 45.5 |
| Change in Net OCI | 1.3 | 0.4 |
| Net income for the period | 9.8 | 5.9 |
| Dividend | -4.6 | - |
| Annual share buyback | -1.2 | - |
| Anti-dilutive share buyback following the sale of AXA IM | -3.5 | -3.5 |
| Undated subordinated debt (including interest charges) | -0.3 | -1.2 |
| Forex | -3.5 | -0.1 |
| Other | -0.6 | 0.3 |
| Closing Shareholders' equity | 47.2 | 47.2 |
Higher organic cash remittance and robust cash position at Holding
- In Euro billion
Net Cash Remittance
| FY24 | FY25 | |
|---|---|---|
| Proceeds related to in-force treaties2(footnote: €0.6bn proceeds related to L&S reinsurance in-force treaties at AXA France and AXA Life Europe.) | 0.6 | |
| Ordinary cash remittance | 7.1 | 7.5 |
| Total Net Cash Remittance | 7.7 | 7.5 |
| Remittance ratio1(footnote: Based on ordinary cash remittance of Euro 7.1 billion in FY24 and Euro 7.5 billion in FY25.) | 82% | 82% |
| FY24 Cash position | 4.0 |
| Net cash remittance from subsidiaries | +7.5 |
| Dividend | -4.6 |
| Annual share buyback | -1.2 |
| Anti-dilutive share buyback following the sale of AXA IM | -3.5 |
| Holding costs and interest expenses | -1.3 |
| Change in net debt | +1.6 |
| M&A and other | +3.1 |
| FY25 Cash position | 5.6 |
|---|
Solvency II at 224%
- In Euro billion
| FY24 | Regulatory & model changes | Normalized capital generation | Operating variance | Economic variance & FX | Dividend & annual share buyback | Management actions, debt & other | FY25 | |
|---|---|---|---|---|---|---|---|---|
| Eligible Own Funds (EOF) | 55.9 | +0.2 | +8.8 | -0.4 | -2.1 | -6.0 | -0.1 | 56.4 |
| Solvency II ratio | 216% | +0pt | +28pts | -1pt | +4pts | -24pts | +2pts | 224% |
| Solvency Capital Requirement (SCR) | 25.9 | 0.0 | +0.6 | 0.0 | -1.2 | 0.0 | -0.2 | 25.2 |
- Foreseeable dividends: €-4.8bn
- Provision for annual share buyback for 2026: €-1.25bn
Key sensitivities
| Ratio as of December 31, 2025 | 224% |
| Interest rate +50bps | +2 pts |
| Interest rate -50bps | -1 pt |
| Corporate spreads +50bps | -1 pt |
| Euro Sovereign spreads +50bps1(footnote: 1. Sensitivity to Euro sovereign spreads assumes a 50bps spread widening of the Euro sovereign bonds vs. the Euro swap curve (applied on sovereign and quasi-sovereign exposures).) | -7 pts |
| Credit migration2(footnote: 2. Sensitivity to credit rating migration assumes 20% of corporate bonds (including private debt) held are downgraded by one full letter (3 notches).) | -4 pts |
| Listed Equity (excl. PE & Infra) +25% | -1 pt |
| Listed Equity (excl. PE & Infra) -25% | +2 pts |
| PE & Infra +25% | +14 pts |
| PE & Infra -25% | -19 pts |
| Inflation swap curve +50bps | -5 pts |
Solvency II – impact of the end of grandfathering period and Solvency II revision
| Metric / Event | Impact / Ratio |
|---|---|
| Ratio as of 31/12/2025 | 224% |
| Impact of the end of grandfathering period on January 1, 2026 | -10pts to 215% |
| Impact of Solvency II revision to come into effect in 1Q27 | +17pts1(footnote: Estimated based on the Solvency Capital Requirement (SCR) and the amount of capital (EOF) under Solvency II as of January 1, 2026, as if the Solvency II revision had come into force on the same date.) |
- Euro 2.4 billion grandfathered debt no longer eligible as capital from January 1, 2026
- No change expected in organic capital generation
- Additional capital flexibility
Conclusion
- Thomas Buberl, Group CEO
Conclusion
- Record results, at the top end of the target range while enhancing reserve prudence
- All businesses in excellent shape, delivering strong growth and profitability
- Diversified franchise, well-positioned to capture future growth opportunities
- Laying foundations for the next plan and confident in delivering sustainable earnings growth
Q&A
- Full Year 2025 Earnings
AXA Investor Relations – Keep in touch
Meet our management
- March: Roadshows — Europe and US
- May 5: 1Q25 Activity Indicators — Paris
- June 2: BNP Paribas Exane CEO Conference — Paris
- June 2-4: Goldman Sachs European Financials Conference — Zurich
- July 31: HY26 Earnings Release — Paris
- September 21: AXA Investor Day — London
Contact us
- Investor Relations
- +33 1 40 75 48 42
- investor.relations@axa.com
Follow us www.axa.com
- YouTube
- AXA logo icon
Appendices
Contents
- 1. Debt and Invested Assets p.31
- 2. Additional P&C disclosures p.36
- 3. Additional IFRS17 disclosures p.41
Gross financial debt and maturity breakdown as of December 31st, 2025
- In Euro billion
Gross financial debt1,2
- Debt gearing: 20.6% (FY24), 22.3% (FY25)
| FY24 | FY25 | Jan 1st 2026 | |
|---|---|---|---|
| Tier 1 | 4.8 | 4.6 | 3.2 |
| Tier 2 | 10.8 | 12.2 | 11.3 |
| Senior debt | 3.5 | 3.5 | 5.8 |
| Total | 19.2 | 20.3 | 20.3 |
- o/w €0.4bn redeemed in Jan 2026 (Tier 2, Jan 1st 2026)
- End of the grandfathering period
Contractual maturity breakdown
| 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031-2039 | ≥2040 | Undated | |
|---|---|---|---|---|---|---|---|---|---|
| Senior debt | 0.5 | - | - | 0.5 | - | 0.9 | 1.5 | - | 0.7 |
| Tier 2 | - | - | - | - | - | 0.7 | - | 10.8 | 4.6 |
| Tier 1 | - | - | - | - | - | - | - | - | - |
- o/w Grandfathered debt
| 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031-2039 | ≥2040 | Undated | |
|---|---|---|---|---|---|---|---|---|---|
| Tier 1 | - | - | - | - | - | - | - | - | 1.4 |
| Tier 2 | - | - | - | - | - | 0.7 | - | 0.2 | - |
Economic maturity breakdown3(footnote: Economic maturity is taking into account the first date of step up calls on institutionally placed subordinated debt. For Solvency 2 RT1 debt, that has no step-up, the undated nature of the instrument is retained for the purpose of this diagram. This should not be construed, nor relied upon, as an indication that the instrument will not be called for redemption when callable. Such decision will depend on several factors, including our capital and liquidity position and the refinancing economics at the prevailing time.)
| 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031-2039 | ≥2040 | Undated | |
|---|---|---|---|---|---|---|---|---|---|
| Senior debt | - | - | - | 0.5 | - | 0.9 | 1.5 | 0.5 | - |
| Tier 2 | - | - | 2.4 | - | 2.0 | 0.7 | 6.4 | - | 0.7 |
| Tier 1 | 0.1 | - | - | 0.1 | - | - | 0.4 | - | 4.0 |
- o/w Grandfathered debt
| 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031-2039 | ≥2040 | Undated | |
|---|---|---|---|---|---|---|---|---|---|
| Tier 1 | - | 0.1 | - | 0.1 | - | - | 0.4 | - | 0.8 |
| Tier 2 | - | - | - | - | - | 0.7 | 0.2 | - | - |
General Account Invested Assets
- FY25 Total General Account invested assets
- Duration gap at -0.4 year
| Invested assets (100%) In Euro billion |
FY25 | % |
|---|---|---|
| Fixed income | 345 | 77% |
| o/w Government bonds | 167 | 37% |
| o/w Corporate bonds and loans | 121 | 27% |
| o/w Other fixed income 1(footnote: Other fixed income includes Asset Backed Securities (Euro 25 billion), Residential Loans (Euro 16 billion), Commercial & Agricultural Loans (Euro 7 billion) and Agency Pools (Euro 8 billion).) | 56 | 13% |
| Real estate | 41 | 9% |
| Infrastructure equity | 10 | 2% |
| Listed equities 2(footnote: Includes hedges. Listed equities excluding hedges at Euro 14 billion.) | 10 | 2% |
| Private equity and hedge funds 3(footnote: Includes Private Equity (Euro 17 billion), Hedge Funds (Euro 5 billion) and Non-listed Equities (Euro 1 billion).) | 23 | 5% |
| Cash | 19 | 4% |
| Policy loans | 2 | 0% |
| Total Insurance Invested Assets 4(footnote: Please refer to the financial supplement for more details.) | 450 | 100% |
Structured and Private Credit assets
| FY25 | % of total G/A1(footnote: G/A: General Account) portfolio | Comments | |
|---|---|---|---|
| Residential Mortgages | 16 | 4% |
- €6bn Dutch mortgages, NHG guaranteed
- €10bn self originated mortgages in Switzerland (56% LTV) and Germany (45% LTV)
CLO & ABS 25 6% - 91% senior CLOs with circa 40% subordination (100% rated AAA-A and 92% rated AAA-AA) Infrastructure debt 8 2% - Skewed towards resilient industries (Telecom, Utilities, Transport) CRE debt 8 2% - Strong sector diversification (mainly logistics, residential and retail), mostly in Europe, and circa 60% LTV Mid-Market lending 10 2%
- Strong diversification with €8m average ticket
- Investments through SMAs with strict underwriting guidelines : senior secured, covenants, restrictions on asset sales and sector allocation
Other 2 0% Total Structured and Private Credit Assets 69 15% o/w 54% participating
Investment portfolio – Fixed Income reinvestment
FY25 Fixed Income Reinvestment
| Government bonds & related (32%) – Average rating: AA |
| Investment grade credit (40%)- Average rating: A |
| ABS/CLO/IG fund financing (21%) |
| Below investment grade credit (7%) |
FY25 Fixed Income Reinvestment Yield
| Category | Yield |
|---|---|
| Public fixed income1(footnote: Government and Corporate bonds and related.) | 3.5% |
| Private & Structured fixed income2(footnote: Private & Structured credit (CLOs, ABS, Infra & CRE debt, Fund financing and Private hybrid).) | 4.7% |
| Total fixed income | 3.9% |
- Euro 57 billion fixed income invested at 3.9%
- Average duration of 9 years
- Includes Euro 19.7 billion of Private & Structured Credit invested at 4.7% (CLOs, ABS, Infra & CRE debt, Fund financing and Private HY)
- Gradual shift from alternative total return assets to Private & Structured credit
Contents
- 1. Debt and Invested Assets p.31
- 2. Additional P&C disclosures p.36
- 3. Additional IFRS17 disclosures p.41
AXA XL Insurance – Large Commercial & Specialty business
- Well diversified across lines of business and geographies
| Line of business | Share (%) |
|---|---|
| Casualty | 35% |
| Property | 29% |
| Specialty | 19% |
| Professional lines1(footnote: Including Cyber) | 17% |
| Geography | Share (%) |
|---|---|
| Americas | 46% |
| Europe & APAC | 35% |
| UK & Lloyds | 19% |
- Leading market positions across lines
- Top 3 globally
- Multinational Programs2(footnote: Source: McKinsey)
- Marine3(footnote: Source: Aon, Guy Carpenter, and Global Market Insights)
- Fine Art & Specie4(footnote: Source: Industry Research Biz (January 2026))
- Managing the cycle to deliver consistent profitability
- Profitability vs. Ex-price growth (%) by line:
- Professional lines
- Casualty
- Specialty
- Property
- (Note: Chart shows positive correlation between ex-price growth and profitability for these lines; specific numeric values not printed)
P&C – Focus on Reserves
Claims reserves ratio
(Net undiscounted claims reserves/Net earned premiums)
| IFRS4 | IFRS17 | |||||||
|---|---|---|---|---|---|---|---|---|
| FY18 | FY19 | FY20 | FY21 | FY22 | FY22 | FY23 | FY24 | FY25 |
| 179% | 185% | 193% | 188% | 189% | 198% | 195% | 180% | 175% |
Technical reserves ratio
(Net undiscounted technical reserves1(footnote: Includes net undiscounted claims reserves and unearned premium reserves.)/Net earned premiums)
| IFRS4 | IFRS17 | |||||||
|---|---|---|---|---|---|---|---|---|
| FY18 | FY19 | FY20 | FY21 | FY22 | FY22 | FY23 | FY24 | FY25 |
| 213% | 227% | 233% | 226% | 227% | 234% | 232% | 216% | 210% |
P&C – 2026 Simplified Group Nat Cat Reinsurance Program1(footnote: Excludes local reinsurance covers;)
- In Euro
| Peril | Capacity | Retention |
|---|---|---|
| EU Windstorm | 4.0bn | 600m |
| Europe Flood | 2.1bn | 450m |
| Europe Earthquake | 2.1bn | 400m |
| NA Hurricane | 1.2bn | 600m2(footnote: Varying retention between MX and NA (400m MX, 600m NA);) |
| NA Earthquake | 1.2bn | 600m2(footnote: Varying retention between MX and NA (400m MX, 600m NA);) |
| Per other perils3(footnote: Other perils include Turkey earthquake, Other Europe and NA perils, South America Earthquake as well as a series of other secondary perils. Capacity varies by peril type.) | 400m |
- Reinsurance segment (illustrative)
- Alternative Capital & Cat Bonds
- Stable retention levels maintained in 2026 as in 2025
P&C – AXA Group earnings deviation with different levels of Nat Cat cost1(footnote: 1. Natural catastrophe cost defined as Aggregate Exceedance Probability (AEP) of all natural perils worldwide, net of tax and reinsurance. Deviation is compared to a normalized level, which are costs associated with natural catastrophes expected in an average year (ca. 4.5 points of estimated FY25 GEP, undiscounted and net of reinsurance).) in 2026
- In Euro billion (net of reinsurance)
Group underlying earnings deviation to average Nat Cat charges in 2026
- net of reinsurance, post-tax
- More severe years: Negative deviation in ca. 40% of cases
- Less severe years: Positive deviation in ca. 60% of cases
| Probability (Percentile) | Earnings Deviation |
|---|---|
| 1/20y (95th) | €-1.2bn |
| 1/10y (90th) | €-0.8bn |
| 1/5y (80th) | €-0.4bn |
| Median (50th) | €+0.1bn |
| 1/5y (20th) | €+0.5bn |
| 1/10y (10th) | €+0.7bn |
| 1/20y (5th) | €+0.8bn |
Average Expected Nat Cat charges
- net of reinsurance, pre-tax
| 2025 | 2026 | |
|---|---|---|
| Average Expected Nat Cat charges (in Euro billion) | 2.6 | 2.7 |
| Estimated impact on GEP | ca. 4.5% | ca. 4.5% |
Contents
- 1. Debt and Invested Assets p.31
- 2. Additional P&C disclosures p.36
- 3. Additional IFRS17 disclosures p.41
P&C – Margin Analysis
Technical Result
| FY25 | Change | |
|---|---|---|
| Current Accident Year Undiscounted Technical Margin | 2,778 | +707 |
| Gross Earned Premiums | 57,656 | +6% |
| Current Accident Year Undiscounted Combined Ratio | 95.2% | -1.0pt |
| o/w Nat Cats | 3.4% | -0.4pt |
| Current Accident Year Discounting | 2,009 | +115 |
| Discounting Ratio (in Combined Ratio points) | -3.5% | +0.0pt |
| Current Accident Year Net Claims reserves | €19.0bn | |
| Duration | 4.0 years | |
| Current Accident Year Discount rate | 2.8% | |
| Prior Years' Reserve Development (PYD) | 622 | -341 |
| PYD ratio | -1.1% | +0.7pt |
Financial Result
| FY25 | Change | |
|---|---|---|
| Investment Income | 3,988 | +435 |
| FY25 Average Assets | €115bn | |
| Asset book yield | 3.5% | |
| FY25 Reinvestment yield1(footnote: Reinvestment yield on fixed income assets.) | 4.3% | |
| Insurance Finance Expenses | -1,358 | -235 |
| FY24 Reserves at locked-in rate | €71bn | |
| Liability book yield | 1.9% |
| FY25 | Change | |
|---|---|---|
| Underlying Earnings before tax | 8,040 | +681 |
| Tax | -2,060 | -169 |
| Affiliates, Minority interests & Other | -108 | -10 |
| Underlying Earnings | 5,872 | +501 |
| Growth vs. FY24 (at constant FX) | +9% |
- FY25 sensitivity to Current Accident Year discount rate changes2(footnote: Parallel shift of the full-year average yield curve (average of monthly opening discount rates of 2025) used for discounting FY25 current accident year net reserve.)
- +25bps: €+0.2bn
- -25bps: €-0.2bn
- 2026e Insurance Finance Expenses (pre-tax): ~ €-1.4bn
- Sensitivity of 2026e Insurance Finance Expenses to changes in 2025 current AY Discount
- +25bps: ~ €-50m
- -25bps: ~ €+50m
- Changes versus FY24 at constant FX.
L&H – Margin Analysis
- Includes scope impact
Technical Result
| FY25 | Change | |
|---|---|---|
| Short-term Technical Margin | 479 | +60 |
| Gross Earned Premiums | 17,416 | +10% |
| All Year Combined Ratio | 97.2% | -0.1pts |
| Long-term Technical Margin | 2,804 | +156 |
| CSM release | 2,954 | +215 |
| Technical experience | -150 | -58 |
- Incl. recapture of Laya
Financial Result
| FY25 | Change | |
|---|---|---|
| Investment Income (non-VFA only) | 2,484 | -1 |
| FY25 Average Assets | €98bn | |
| Asset book yield | 2.5% | |
| FY25 Reinvestment yield1(footnote: Reinvestment yield on fixed income assets.) | 3.8% | |
| Insurance Finance Expenses (non-VFA only) | -1,538 | -9 |
| FY24 Reserves at locked-in rate | €62bn | |
| Liability book yield | 2.5% |
| FY25 | Change | |
|---|---|---|
| Underlying Earnings before tax | 4,229 | +205 |
| Tax | -800 | 65 |
| Affiliates, Minority interests & Other | 72 | -51 |
| Underlying Earnings | 3,501 | +219 |
| Growth vs. FY24 (at constant FX) | +7% |
Life & Health FY25 CSM Key Sensitivities
| Baseline | 33.3 |
| Interest rates +50bps | -0.8 |
| Interest rates -50bps | 0.6 |
| Sovereign spreads +50bps | -1.9 |
| Sovereign spreads -50bps | 1.9 |
| Corporate spread +50bps | -0.8 |
| Corporate spread -50bps | 0.7 |
| Equities +25% | 1.8 |
| Equities -25% | -2.2 |
Contents
- 1. Debt and Invested Assets p.31
- 2. Additional P&C disclosures p.36
- 3. Additional IFRS17 disclosures p.41
Expanding AXA’s role in society: AXA for Progress Index1(footnote: AXA’s Sustainability Statement is subject to completion of a certification with limited assurance by AXA Group’s auditors and will be presented to the AXA Board of Directors for approval on March 11, 2026.)
As a GLOBAL INVESTOR
| Target | 2025 Result |
|---|---|
| €5bn2(footnote: Scope: corporate and sovereign debt, real estate and private assets. Timeframe: per annum through 2030.) in climate transition financing per year | €6.4bn |
| >€500m2(footnote: Scope: corporate and sovereign debt, real estate and private assets. Timeframe: per annum through 2030.) in community resilience financing per year | €1.4bn |
As a GLOBAL INSURER
| Target | 2025 Result |
|---|---|
| €6bn3(footnote: Scope: AXA France, AXA Germany, AXA Switzerland, AXA UK & Ireland, AXA Belgium, AXA Hong Kong, AXA Mexico, and AXA XL; Unit: Gross Written Premiums (GWP); Timeframe: cumulative 2024-2026.) in P&C GWP to support transition underwriting (cumulative 2024-2026) | €4.6bn |
| >20,0004(footnote: Scope: Commercial lines portfolio of AXA France, AXA Germany, AXA Switzerland, AXA UK, AXA Belgium, AXA Hong Kong, AXA Mexico, and AXA XL; Climate solutions & services include (i) training/education, (ii) risk assessment/awareness, (iii) gap analysis, (iv) prevention/adaptation solution, and/or (v) crisis management/remediation response. Timeframe: cumulative 2024-2026. Following strong support within the Group for climate adaption solutions & services in 2024 and 2025, AXA is proposing a significant increase in its target for the 2024-2026 period, from >9,000 to >20,000.) climate adaptation solutions & services (cumulative 2024-2026) Target revised in 2025 | 19,698 Cumulative 2024-2025 |
| >20m5(footnote: Low-income to mass market segments in emerging markets and modest income segments in mature markets.) inclusive insurance customers by 2026 | 20.6m |
As a COMPANY
| Target | 2025 Result |
|---|---|
| >80,0006(footnote: Number of employees who have been trained on climate change adaptation, completing a training under the AXA Sustainability Academy. Timeframe: cumulative 2024-2026.) AXA Group employees trained on climate adaptation by 2026 | 46,420 |
| Contribute to Net-Zero -50%7(footnote: Variation of AXA Group absolute carbon emissions (scope: energy Scopes 1 and 2, car fleet and business travel). Timeframe: 2019-2030.) by 2030 in absolute carbon emissions and offset of residual emissions8(footnote: Carbon credits from projects that focus on capturing and storing carbon emissions from the atmosphere using nature-based or technical solutions (e.g. restorative agriculture, forest restoration or carbon capture and storage).) | -64% Reduction against 2019 |
| 50% Percentage of AXA Group employees engaged in volunteering activities by 2026 | 56% |
Sustainability Performance & Ratings
- S&P Global
- 2025 percentile: 97th 1(footnote: The CSA ranking is a key performance indicator for AXA Group, used to calculate the grant of Long-Term Incentives (more precisely AXA Restricted Shares). Results as of February 6th, 2026.) in Dow Jones Best-in-Class Europe & World indices
- MSCI
- 2025 score: AAA
- CDP
- 2025 score: B
- MORNINGSTAR SUSTAINALYTICS
- 2025 ESG Risk Rating: 17.0– Low risk
- FTSE RUSSELL An LSEG Business
- 2025 score: 4.3/5 in FTSE4Good Index Series
Scope
- France: includes insurance activities, banking activities and holding.
- Europe: includes Switzerland (insurance activities), Germany (insurance activities and holding), Belgium and Luxemburg (insurance activities and holding), United Kingdom and Ireland (insurance activities and holding), Spain (insurance activities and holdings), Italy (insurance activities), Prima (insurance activities) and AXA Life Europe (insurance activities).
- AXA XL: includes insurance and reinsurance activities and holding.
- Asia, Africa & EME-LATAM: includes (i) Asia: Japan (insurance activities and holding), Hong Kong (insurance activities), Thailand P&C, China P&C, South Korea, and Asia Holdings which are fully consolidated, and China L&S, Thailand L&S, the Philippines L&S and P&C, Indonesia L&S and India (Life activities disposed on March 11, 2024 and holding) businesses which are consolidated under the equity method and contribute only to NBV, PVEP, the underlying earnings and net income, (ii) Africa : Morocco (insurance activities and holding) and Nigeria (insurance activities and holding), Egypt (insurance activities and holding) which are fully consolidated, (iii) EME-LATAM: Mexico (insurance activities), Colombia (insurance activities), Brazil (insurance activities and holding) and Türkiye (insurance activities and holding) which are fully consolidated as well as Russia (Reso) (insurance activities) which consolidated under the equity method and contributes only to the net income, (iv) AXA Mediterranean Holdings.
- Transversal & Other: includes AXA Assistance, AXA Liabilities Managers, AXA and other Central Holdings.
- AXA Investment Managers (until July 1, 2025): includes AXA Investment Managers, Select (previously referred to as Architas) and Capza which are fully consolidated and Asian joint ventures which are consolidated under the equity method.
- Unless otherwise specified herein, all comparative figures for going back to 2023 are under the IFRS17/9 accounting standards that became effective on January 1, 2023. Figures for financial periods prior to 2023 have not been restated under IFRS17/9 and are presented under IFRS4, the applicable accounting standard that preceded the implementation of IFRS17/9
Glossary
- Capital-light G/A products: encompass all products with no guarantees, with guarantees at maturity only or with guarantees equal to or lower than 0%
- Contractual Service Margin (CSM): a component of the carrying amount of asset or liability for a group of insurance contracts representing the unearned profit to be recognized as services are provided to policyholders
- CSM release: a portion of CSM stock net of reinsurance at the end of the defined period flowing through profit and loss representing the estimated profit earned by the insurer for providing insurance services during the reporting period
- Economic variance: corresponds to the variance of the year-end CSM arising from changes in market conditions, net of the underlying return on in-force
- Financial result: consists of investment income on assets backing BBA and PAA contracts as well as assets backing shareholder’s equity, net of the insurance finance expenses (IFE) defined as the unwind of the present value of future cash flow
- Gross Written Premiums and Other Revenues (GWP & Other Revenues): represent the insurance premiums collected during the period (including risk premiums, premiums from pure investment contracts with no discretionary participating features, fees and revenues, net of commissions paid on assumed reinsurance business). Other Revenues represent premiums and fees collected on activities other than insurance (i.e. banking, services, and asset management activities)
- New Business Value (NBV): the value of newly issued contracts during the current year. It consists of the sum of (i) the new business contractual service margin, (ii) the present value of the future profits of short-term newly issued contracts during the period, carried by Life entities, considering expected renewals, (iii) the present value of the future profits of pure investment contracts accounted for under IFRS 9, net of (iv) the cost of reinsurance, (v) taxes and (vi) minority interests
- New Business Contractual Service Margin (NB CSM): a component of the carrying amount of the asset or liability for newly issued insurance contracts during the period, representing the unearned profit to be recognized as insurance contract services are provided
- New Business Value margin (NBV margin): ratio of (i) NBV, representing the value of newly issued contracts during the current year, to (ii) PVEP
- Operating variance: the variation of the year-end CSM versus the expected at opening due to (i) the differences between realized and expected operational assumptions, (ii) changes in assumptions such as mortality, longevity, lapses and expenses, and (iii) impact of model changes. Operating variance is net of reinsurance
- Present value of expected premiums (PVEP): the new business volume, equal to the present value at the time of issue of the total premiums expected to be received over the policy term. PVEP is discounted at the reference interest rate and PVEP is Group share
- Technical experience: consists the impacts on the underlying earnings if (i) the difference between the expected and incurred cash-flows of the defined period, (ii) the risk adjustment release, (iii) the changes in onerous contracts, and (iv) the other long-term elements which are mainly composed of non-attributable expenses
- Underlying return on in-force: represents the release of Time Value of Options & Guarantees (TVOG) plus the unwind of CSM at the reference rate plus the underlying financial over-performance
Thank you
- Full Year 2025 Earnings